에 대한 최신 뉴스 AbbVie (NYSE:ABBV) 주식

ABBVIE INC

AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Lawsuit against drug companies

Opinion

Markets

Trading Ideas

ABBV

AMGN

REGN

SEPN

한 미디어 행사에서 트럼프 대통령은 기자들에게 59%에서 90% 사이의 가격 인하를 목표로 하고 있다고 말하며 제약사들에게 30일의 시간을 주었다. 월가는 이 소식을 받아들였고, 행정명령이 발표된 날 주요 바이오제약 주식의 주가는 하락했지만 대부분의 업계 주식은 반등했다.트럼프의 행정명령으로 인해 반등에 그치지 않고 급등할 것으로 예상되는 제약주 3가지를 소개한다.

트럼프의 약가 인하로 수혜 입을 수 있는 제약주 3가지

unnamed

Biotech

Equities

Long Ideas

화이자(NYSE:PFE)는 10년래 최저 밸류에이션에 가까운 거래에도 불구하고, 특히 씨젠 인수를 통해 종양학 혁신을 통해 장기적인 성장을 위해 전략적으로 재편하고 있다. 시장은 여전히 코로나19 관련 매출 감소와 다가오는 특허 절벽에 집착하고 있지만, 투자자들은 회사의 극적으로 확장된 종양학 파이프라인, 탄탄한 잉여현금흐름, 2025~2026년에 상당한 주가 상승을 이끌 수 있는 여러 촉매제의 잠재력을 간과하고 있다.

화이자, 2025년에 강력하게 반등할 이유는?

Abbvie

Technicals

애브비(NYSE:ABBV)의 주가가 화요일 0.59% 상승 마감했다. 주가는 상승세에 있었다. 지난주 동안, 12% 이상 상승했다.하지만 지금은 과매수 상태이다. 이는 판매자들이 시장에 진입할 수 있게 하고, 이들이 애브비 주가를 압박할 수 있다. 벤징가의 기술 분석가 팀은 이를 오늘의 주식으로 선정했다.

오늘의 주식: 최근 상승으로 과매수 상태인 애브비, 반전이 다가올 수 있을까?

AbbVie Inc

A surge in demand for weight-loss and diabetes medications, paired with fears of incoming tariffs, has propelled Ireland to the center of a pharmaceutical trade boom with the U.S., dramatically widening the <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">bilateral trade imbalance</a>.
This year alone, $36 billion worth of hormone ingredients—essential for popular drugs like GLP-1 treatments and insulin analogs—have been flown from Ireland to the U.S., more than doubling last year&#8217;s total.
The Wall Street Journal <a target="_blank" href="https://www.wsj.com/health/pharma/how-weight-loss-drugs-blew-out-the-u-s-trade-deficit-2d8c668c" rel="noreferrer noopener">stated</a> that these pharmaceutical ingredients weighed 23,400 pounds, were highly concentrated, and shipped in temperature-controlled containers.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45998123/scholar-rocks-atrophy-drug-when-combined-with-eli-lillys-zepbound-shows-around-55-better-muscle-preservation-in-weight-loss-study" rel="noreferrer noopener">Scholar Rock&#8217;s Atrophy Drug When Combined With Eli Lilly&#8217;s Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study</a>
Nearly all were bound for Indiana, where Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), the maker of blockbuster drugs Zepbound and Mounjaro, is based.
The company began manufacturing these products in its Kinsale, Ireland facility last year and is now preparing to seek U.S. approval for a weight-<a target="_blank" href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" rel="noreferrer noopener">loss pill, orforglipron</a>.
This airlift of peptide and protein-based hormones, compounds that regulate appetite and metabolism, has played a key role in pushing Ireland to the second spot on U.S. goods-trade deficits, trailing only China.
In the first four months of 2025, the U.S. imported $71 billion in goods from Ireland, with hormone ingredients accounting for nearly half.
The rush stems from both commercial and geopolitical pressures. Former President Donald Trump&#8217;s shifting trade policies have triggered stockpiling by pharmaceutical companies racing to beat tariff deadlines.
A Section 232 investigation launched in April could lead to new levies on imported <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44847222/trump-administration-opens-probe-into-foreign-drug-imports-eyes-tariffs-under-national-security-law" rel="noreferrer noopener">drugs and active ingredients</a>.
The report added that Ireland, home to just 5.4 million people, is a hub for U.S. pharmaceutical manufacturing, partly due to its favorable tax structure.
Giants like AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) produce leading treatments such as Botox and Keytruda there.
Ireland&#8217;s central bank <a target="_blank" href="https://www.benzinga.com/markets/eurozone/25/06/46034817/us-multinationals-including-pharma-firms-power-over-5-of-eurozone-economy-ecb-says" rel="noreferrer noopener">attributed</a> a nearly 10% GDP growth in Q1 to soaring pharma exports.
However, the trade imbalance has drawn scrutiny. Ireland was recently added to the U.S. Treasury Department&#8217;s currency manipulation watchlist. Dan O&#8217;Brien of Dublin&#8217;s Institute of International and European Affairs said the attention is &#8220;definitely not welcome,&#8221; especially as Ireland alone accounts for a large share of the U.S.-EU deficit.
The logistical strain is also evident. Pharma shipments from Ireland to the U.S. more than doubled in March and April, with logistics firms working overtime. Lufthansa Cargo and Kuehne + Nagel reported increased volumes, although activity began to slow in April as U.S. warehouses filled up.
As the White House pushes to onshore drug manufacturing, companies like Lilly and Merck are ramping up domestic investments, aiming to reduce reliance on foreign supply chains amid regulatory uncertainty.
Price Action: LLY stock is down 2.55% at $765.05&nbsp;at the last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/06/46003836/eli-lillys-1-3-billion-verve-deal-signals-confidence-in-gene-editing-space-analyst" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst</a></li>
</ul>
Photo by M7kk via Shutterstock

Large Cap

News

Health Care

Media

General

Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices.
What Happened: The clash, unfolding as of Friday, has reignited discussions on Pharmacy Benefit Managers (PBMs) and Big Pharma's tax practices, with the Senate poised to address reform amid rising public scrutiny.
Enter Cuban, the Dallas Mavericks owner and founder of Cost Plus Drugs, who fired back with a pointed correction.
In a post quoting Warren, Cuban argued that PBMs—not Big Pharma—are the true culprits behind inflated drug prices.
&#8220;PBMs corrupt healthcare,&#8221; he wrote, explaining that these intermediaries control formularies and manipulate prices to maximize rebate revenue, with <a href="https://www.benzinga.com/25/05/45487788/trumps-drug-price-order-hits-pbms-hardest-cvs-cigna-unh-in-focus-as-experts-highlight-racket-and-pricing-distortion">three major PBMs</a> negotiating over 90% of rebates for commercial insurance plans. 
Warren, in her post, had blamed pharmaceutical giants like Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) for charging Americans the &#8220;highest drug prices in the world&#8221; while paying &#8220;zero dollars in federal taxes.&#8221;
Citing data from her Senate Finance Committee role, Warren highlighted how these companies, alongside AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), have exploited tax loopholes from the 2017 Tax Cuts and Jobs Act to shield billions in profits.
&#8220;Republicans want to make it worse. I&#8217;m fighting back,&#8221; she declared, sharing <a href="https://www.cnbc.com/2025/06/17/pfizer-merck-jj-others-face-scrutiny-over-tax-loophole-extension.html">a</a> CNBC headline and urging action against what she calls a &#8220;rigged tax system.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">No. It&#39;s because PBMs corrupt healthcare. Big Pharma wishes they could set their own pricing. They don&#39;t. PBMs control formularies and manipulate prices, in exchange for providing pharma access to patients. It&#39;s how they maximize rebate revenue. In fact, 3 PBMs NEGOTIATE… <a href="https://t.co/GpN4mnzvOM">https://t.co/GpN4mnzvOM</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1935705831930298562?ref_src=twsrc%5Etfw">June 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46013679/dan-ives-says-market-is-massively-underestimating-this-ai-play-urges-investors-to-look-beyong-mag-7">Dan Ives Says Market Is ‘Massively Underestimating' This AI Play, Urges Investors To Look Beyond Mag 7</a>
Why It Matters: Cuban has been a c<a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications">ritic of the healthcare system</a>, saying that it should be simple. According to him, it&#8217;s become overly complicated by big insurance companies and PBMs.
These groups, he says, act as middlemen, controlling not just the costs but also the accessibility of care.
He blames PBMs for lack of transparency, inflated specialty drug prices, rebate distortion, formulary restrictions, and &#8220;Sh–ing on&#8221; on independent pharmacies.
Some significant firms engaged in the PBM business listed in the U.S. include;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>51.15%</td>
<td>9.57%</td>
</tr>
<tr>
<td>Cigna Group. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td>14.54%</td>
<td>-6.95%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-39.11%</td>
<td>-36.60%</td>
</tr>
</tbody>
</table>
</figure>
Meanwhile, here is how some pharmaceutical sector ETFs have performed;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>1.69%</td>
<td>-4.48%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-0.49%</td>
<td>-1.85%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-3.23%</td>
<td>-1.64%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-4.06%</td>
<td>2.61%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>20.55%</td>
<td>22.94%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-5.44%</td>
<td>-6.27%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-23.49%</td>
<td>-14.63%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were mixed in premarket on Friday. The SPY was down 0.30% at $595.67, while the QQQ was 0.015% higher at $529.07, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46016347/this-stock-just-popped-30-in-5-days-now-expert-says-it-looks-potentially-explosive">This Stock Just Popped 30% In 5 Days — Now Expert Says It ‘Looks Potentially Explosive'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Insurance

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'

AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) on Wednesday released topline results from its Phase 3 TEMPLE study evaluating the tolerability, safety, and efficacy of atogepant (QULIPTA/AQUIPTA, 60 mg once daily) compared to the highest tolerated dose of topiramate (50, 75 or 100 mg/day) in adult patients with a history of four or more <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45992220/abbvie-announces-new-data-demonstrating-atogepant-qulipta-aquipta-achieves-superiority-across-all-" rel="noreferrer noopener">migraine days per month</a>.
The study met the primary endpoint of treatment discontinuation due to adverse events (AEs), demonstrating that atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, had fewer discontinuations due to AEs than topiramate, an anticonvulsant medication also approved for migraine prevention.
Over the 24-week double-blind treatment period, discontinuation due to AEs was significantly lower with atogepant (12.1%) compared to topiramate (29.6%), representing a relative risk of 0.41.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45418687/fda-fast-tracks-abbvies-new-lung-cancer-therapy-emrelis-for-tough-lung-cancer-cases" target="_blank" rel="noreferrer noopener">FDA Fast-Tracks AbbVie&#8217;s New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases</a>
The study also met all six secondary endpoints, including a key measure of clinical efficacy: 64.1% of patients on atogepant achieved a ≥50% reduction in mean monthly migraine days (MMD) during months 4 to 6 of the double-blind treatment period compared to 39.3% of patients on topiramate (p&lt;0.0001).&nbsp;
Atogepant, marketed as AQUIPTA&nbsp;in the EU and QULIPTA&nbsp;in the U.S.,&nbsp;Canada,&nbsp;Israel, and&nbsp;Puerto Rico, is approved in 60 countries. It is a once-daily oral CGRP receptor antagonist used to prevent episodic and chronic migraine in adults.
Full results from the TEMPLE study will be presented at an upcoming medical meeting.
Recently, AbbVie said the Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk&nbsp;myelodysplastic syndrome (HR-MDS) did not meet the primary endpoint of overall survival with a hazard ratio of 0.908; stratified log-rank, p=0.3772. No new safety <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45975622/abbvies-cancer-drug-venetoclax-falls-short-in-phase-3-combination-trial-for-myelodysplastic-syndromes" rel="noreferrer noopener">signals were observed</a>.
Price Action: ABBV stock is trading higher by 0.48% to $186.36 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/02/43921470/axsome-says-symbravo-hits-primary-goal-in-late-stage-migraine-trial-in-patients-experiencing-inadequate-response-to-commonly-used-drugs" target="_blank" rel="noreferrer noopener">Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs</a></li>
</ul>
Photo via Shutterstock

AbbVie's Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial

<ul>
<li>TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month1</li>
<li>Atogepant met the primary endpoint of fewer treatment discontinuations attributed to adverse events versus topiramate, and all six secondary endpoints achieved statistical significance for superiority versus topiramate, demonstrating clinical efficacy1</li>
<li>Full results from the TEMPLE study will be presented at an upcoming medical meeting</li>
</ul>

AbbVie Announced Topline Results From Its Phase 3 TEMPLE Trial Of Atogepant Compared To The Highest Tolerated Dose Of Topiramate In Migraine Patients, The Study Met The Primary Endpoint

Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial public offering, aiming to raise up to $423.5 million.&nbsp;
The Irving, Texas-based firm, backed by investment giants Sixth Street and Neuberger Berman, has already conducted 6.5 million molecular tests across 849,000 patient cases, establishing partnerships with over 100 biopharmaceutical firms, including Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), according to its <a href="https://www.sec.gov/Archives/edgar/data/2019410/000110465925057593/tm2415719-16_s1a.htm">prospectus</a> filed with the U.S. Securities and Exchange Commission.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
<h2 class="wp-block-heading">Valuation Context and Financial Performance</h2>
The $5.35 billion target—based on 23.5 million shares priced between $16 and $18 each—marks a notable shift from Caris' 2021 private valuation of $7.83 billion, Reuters reported, reflecting both market recalibration and the challenges of commercializing precision medicine.&nbsp;
According to its filing, Caris generated $412.3 million in revenue in 2024—a 35% year-over-year increase—while posting a net loss of $257.1 million. In Q1 2025, the company reported $120.9 million in revenue and a narrowed net loss of $127 million, compared to $80.7 million in revenue and a $134.1 million loss during the same period in 2024, according to its filing—signaling improving margins and sustained top-line growth.
At its proposed valuation, Caris would trade at approximately 13 times sales, a premium to peers like Guardant Health (NASDAQ: GH) and Tempus AI (NASDAQ: TEM), Reuters reported.&nbsp;
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
<h2 class="wp-block-heading">Technology and Competitive Edge</h2>
According to the company's website, Caris was founded in 2008 by entrepreneur David D. Halbert, who was inspired by his father's cancer battle to develop more effective, data-driven diagnostics. Today, the company operates from its North Texas headquarters and has offices in Phoenix, New York, Cambridge, Massachusetts, Tokyo, Japan, and Basel, Switzerland, serving both U.S. and international markets.
Caris' proprietary AI platform, which integrates molecular science with machine learning, analyzes comprehensive genomic, transcriptomic, and proteomic data to guide cancer treatment. The company holds 27 issued patents along with over 170 applications pending worldwide, according to its website. Its flagship MI Cancer Seek test, cleared by the U.S. Food and Drug Administration in 2023, detects early-stage malignancies with what the company claims is unmatched accuracy, the <a href="https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek/#:~:text=MI%20Cancer%20Seek%20is%20available,Halbert%2C%20DSc%20(h.c.).">company</a> said at the time.&nbsp;
<h2 class="wp-block-heading">Investor Sentiment and Sector Implications</h2>
Caris will trade on the Nasdaq under the symbol CAI The offering is led by BofA Securities, J.P. Morgan Securities LLC, Goldman Sachs &amp; Co. LLC, and Citigroup Global Markets. <a href="https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-diagnostics-market">Grand View Research</a> projects a 22.5% CAGR in the AI cancer diagnostics market through 2030, highlighting strong growth potential in this sector.
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>
Neuberger Berman has indicated it may purchase up to $75 million worth of shares in the IPO—signaling insider confidence in the company's long-term potential, according to Reuters.
<h2 class="wp-block-heading">Regulatory and Market Risks</h2>
Caris Life Sciences currently has one FDA-cleared diagnostic test, MI Cancer Seek, according to its filing.&nbsp;
Caris' pipeline includes investigational tools like FOLFIRSTai, an AI-based test for predicting chemotherapy response in metastatic colorectal cancer. While clinically validated, it remains unapproved by the FDA, according to the SEC filing, and stricter regulations could delay its commercialization.
<h2 class="wp-block-heading">Conclusion: A Litmus Test for AI Biotech</h2>
Caris's proposed IPO is drawing attention as a potential marker for the viability of AI-driven healthcare, with Reuters noting the offering comes amid renewed interest in precision diagnostics.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
</ul>
Image: Shutterstock

MRNA

AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine

AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) on Monday announced an update from the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">myelodysplastic syndrome (HR-MDS)</a>.
MDS is a group of cancers in which the bone marrow doesn&#8217;t produce enough healthy blood cells.
The primary outcome measure is overall survival (OS). Key secondary outcome measures include a modified overall response (mOR) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45948002/abbvie-provides-update-on-verona-trial-for-newly-diagnosed-higher-risk-myelodysplastic-syndromes" rel="noreferrer noopener">and complete remission (CR)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45079377/abbvie-scores-fda-approval-for-its-blockbuster-drug-rinvoq-to-treat-type-of-arthritis" rel="noreferrer noopener">AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis</a>
The trial did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772. No new safety signals were observed.
Results from the VERONA trial will be available in a future medical congress and/or publication.
The treating physician will inform any patients who received venetoclax in combination with azacitidine through participation in the MDS clinical trials.&nbsp;
These data do not impact any currently approved indications for venetoclax.
In the first quarter, AbbVie reported Venclexta&#8217;s revenues were&nbsp;$665 million, <a target="_blank" href="https://www.benzinga.com/25/04/45011116/abbvie-q1-earnings-come-ahead-of-expectations-ceo-says-well-positioned-for-long-term" rel="noreferrer noopener">up 8.3% year over year (+12.3%)</a>.
Last week, the U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie&#8217;s Mavyret (glecaprevir/pibrentasvir) to include treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45890526/fda-expands-abbvies-mavyret-label-to-include-pediatric-patients-with-hepatitis-c-infection" rel="noreferrer noopener">or with compensated cirrhosis.</a>
With this approval, Mavyret is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate.
HCV is a highly infectious blood-borne disease affecting the liver.
<h2 class="wp-block-heading">AbbVie Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at AbbVie, an investor could make an assessment about a stock&#8217;s long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For AbbVie, the 200-day moving average sits at $188.78, according to <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">Benzinga Pro</a>, which is below the current price of $189.54. For more on charts and trend lines, <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: ABBV stock is trading lower by 1.47% to $188.06 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45946402/incytes-experimental-therapy-shows-platelet-normalization-and-safety-in-rare-blood-cancer-trials-across-doses" target="_blank" rel="noreferrer noopener">Incyte&#8217;s Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Movers

AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes

AbbVie Says Phase 3 VERONA Trial In Newly Diagnosed Higher-Risk Myelodysplastic Syndromes Did Not Meet Primary Endpoint Of Overall Survival

Editor's Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.
The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Mavyret (glecaprevir/pibrentasvir) to include treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis <a href="https://www.benzinga.com/general/health-care">or with compensated cirrhosis.</a>
Glecaprevir, one of the two DAAs in Mavyret, was Discovered by Enanta Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) and developed and commercialized by AbbVie.
Also Read: <a href="https://www.benzinga.com/25/05/45621885/abbvie-highlights-cancer-trial-data-presentation-at-upcoming-asco-annual-meeting" target="_blank" rel="noreferrer noopener">AbbVie To Present Cancer Trial Data At Upcoming ASCO Event</a>
With this approval, Mavyret is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate.
HCV is a highly infectious blood-borne <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45889177/u-s-fda-approves-expanded-indication-for-abbvies-mavyret-glecaprevirpibrentasvir-as-first-and-only" rel="noreferrer noopener">disease affecting the liver</a>.
The United States&nbsp;is expected to incur&nbsp;around $120 billion&nbsp;in total medical costs over the next 10 years through 2035 linked to chronic liver disease and other related conditions caused by untreated HCV.
Data from the Phase 3, multicenter, single-arm prospective study evaluating the safety and efficacy of Mavyret eight-week treatment in adults with acute HCV infection supported the label expansion.
The study results showed Mavyret to be a highly efficacious treatment for people with acute HCV.
The majority of the adverse events reported were mild or moderate in severity. Fatigue, asthenia, headache, and diarrhea were the most common adverse events.
In 2017, the FDA approved Mavyret to <a target="_blank" href="https://news.abbvie.com/2019-09-26-AbbVie-Receives-FDA-Approval-of-MAVYRET-R-glecaprevir-pibrentasvir-to-Shorten-Treatment-Duration-to-Eight-Weeks-for-Treatment-Naive-Patients-with-Chronic-Hepatitis-C-and-Compensated-Cirrhosis-Across-All-Genotypes" rel="noreferrer noopener">treat</a> adults with chronic (lasting a long time) hepatitis C virus (hep C) genotypes 1, 2, 3, 4, 5, or 6 infections without cirrhosis or with compensated cirrhosis.
In 2019, the FDA approved Mavyret to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients across all genotypes (GT1-6).
Price Action: ABBV stock is trading higher by 1.54% to $192.43 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/03/44202109/atea-pharma-cuts-workforce-by-25-expects-15-million-in-cost-savings-plans-phase-3-hepatitis-c-trial" target="_blank" rel="noreferrer noopener">Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial</a></li>
</ul>
Photo by Tada Images via Shutterstock

ENTA

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)

AbbVie's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) short percent of float has fallen 20.35% since its last report. The company recently reported that it has 15.89 million shares sold short, which is 0.9% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>AbbVie Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749672061_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AbbVie has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AbbVie's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, AbbVie's peer group average for short interest as a percentage of float is 6.66%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About AbbVie?

Politics

At Goldman Sachs Conference, AbbVie CEO Reportedly Says Conversations With President Donald Trump On Drug Pricing Reform Have Been "Productive"; On Drug Pricing Reform, Says "Quite A Long Way To Go" In Terms Of Reaching An Agreement

A June filing shows that Representative Robert Bresnahan reported a purchase in AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), valued between $28,028 and $420,000. The transaction date is listed as May 15, 2025, with the report published on June 9, 2025.
At present, AbbVie shares are trading up 0.34% at $189.81.
<h3>What Representative Has Been Trading Recently</h3>
In the past three years, Robert Bresnahan made 589 stock trades totaling more than $1.77 million. The largest trades involved stocks like Alphabet and Berkshire Hathaway Inc. New Common Stock. Their most notable trades made recently include key transactions: 
<ul>
<li>Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>): $15,001 - $50,000 Purchase</li>
<li>ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>): $15,001 - $50,000 Purchase</li>
<li>Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>): $15,001 - $50,000 Sale</li>
</ul>
Here's a summary of Robert Bresnahan's recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Netflix</td>
<td>NFLX</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-05-17</td>
</tr>
<tr>
<td>NVIDIA</td>
<td>NVDA</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-05-16</td>
</tr>
<tr>
<td>Tesla</td>
<td>TSLA</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-05-16</td>
</tr>
<tr>
<td>Veeva Systems</td>
<td>VEEV</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-05-16</td>
</tr>
<tr>
<td>Advanced Micro Devices</td>
<td>AMD</td>
<td>STOCK</td>
<td>$15,001 - $50,000</td>
<td>P</td>
<td>2025-05-15</td>
</tr>
</tbody>
</table>
To keep an eye on Robert Bresnahan's trades and other government stock activity, check out our <a href="https://www.benzinga.com/gov-trades/members/robert-bresnahan">real-time tracking tool</a>!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Recent Filing Shows That Rep. Robert Bresnahan Bought Over $28K Worth of AbbVie Stock

AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">rheumatoid arthritis</a>.
In the 424-patient 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45757627/anaptys-announces-positive-rosnilimab-data-updated-through-six-months-in-robust-phase-2b-trial-in-" rel="noreferrer noopener">over six months</a>.
Furthermore, responses were then durable for at least two months off the drug.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42445688/anaptysbio-discontinues-investment-in-eczema-candidate-after-disappointing-data" rel="noreferrer noopener">AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data</a>
Rosnilimab was safe and well tolerated, particularly compared to standard-of-care biologics or JAKs.
All three doses (100mg Q4W, 400mg Q4W, 600mg Q2W) achieved statistically significant reductions in DAS-28 CRP and ACR20 at Week 12 versus placebo.
CDAI LDA (≤10) was achieved by 45% of 318 rosnilimab patients by Week 12, increasing to 69% (220 responders) across all doses by Week 14.
The company aims to complete its Phase 2 study for rosnilimab in ulcerative colitis/UC, with initial data expected in the fourth quarter of 2025.
As of the March 11, 2025&nbsp;data cutoff date, 83% were still in LDA at Week 34 across all doses. Of the remaining 17% of patients who did not sustain CDAI LDA at Week 34, most remained near the cutoff of CDAI=10, with a median CDAI of 13.
Rosnilimab demonstrated clinically meaningful improvements that deepened through Week 28 across multiple validated patient-reported outcomes, including the pain visual analog scale (VAS) and the health assessment questionnaire, or HAQ-Disability Index (DI), a self-reporting tool to measure function and disability.
HC Wainwright analyst Emily Bodnar wrote on Wednesday, &#8220;Given the data showcase a positive holistic story for rosnilimab in RA, we are increasingly positive on upcoming UC data.&#8221;
Bodnar upgraded AnaptysBio from Neutral to Buy, raising the price target<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings" target="_blank" rel="noreferrer noopener"> from $22 to $38</a>.
HC Wainwright Highlights Competitor Datasets
Data using non-responder imputation (NRI) from Week 24 of the SELECT-CHOICE trial, which compared AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Rinvoq vs Bristol Myers Squibb&nbsp;&amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Orencia in rheumatoid arthritis (RA), showed similar results for both drugs. These findings align with the results seen for the company&#8217;s rosnilimab at Week 28, even though about 29% of patients had previously been treated with JAK inhibitors.
In contrast, Eli Lilly And Co&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) now-discontinued PD-1 agonist peresolimab showed a drop in CDAI LDA rates—from 55% at Week 14 to 37% at Week 24. This is notably lower than the 53–63% range reported for rosnilimab at Week 28.
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is also set to present early data for its PD-1 agonist at the upcoming EULAR conference, though its study is smaller than AnaptysBio&#8217;s.
Price Action: ANAB stock is down 12.1% at $20.66 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45769045/tariffs-ai-and-trade-war-apples-smartphone-growth-to-take-a-hit-experts-say" target="_blank" rel="noreferrer noopener">Tariffs, AI And Trade War: Apple&#8217;s Smartphone Growth To Take A Hit, Experts Say</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Upgrades

Analyst Ratings

ANAB

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTRA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$175.00</td>
<td>$36.9K</td>
<td>10</td>
<td>1.3K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$18.00</td>
<td>$25.4K</td>
<td>49.9K</td>
<td>898</td>
</tr>
<tr>
<td>SRDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$30.00</td>
<td>$190.0K</td>
<td>502</td>
<td>500</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$310.00</td>
<td>$43.5K</td>
<td>3.0K</td>
<td>494</td>
</tr>
<tr>
<td>AKBA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.50</td>
<td>$31.0K</td>
<td>438</td>
<td>350</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$70.00</td>
<td>$88.3K</td>
<td>576</td>
<td>217</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$710.00</td>
<td>$63.4K</td>
<td>25</td>
<td>13</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$115.00</td>
<td>$87.5K</td>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/18/26</td>
<td>$120.00</td>
<td>$35.6K</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For NTRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), we notice a call option trade that happens to be bullish, expiring in 107 day(s) on September 19, 2025. This event was a transfer of 26 contract(s) at a $175.00 strike. The total cost received by the writing party (or parties) was $36.9K, with a price of $1420.0 per contract. There were 10 open contracts at this strike prior to today, and today 1350 contract(s) were bought and sold. 
• For TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we notice a call option sweep that happens to be bullish, expiring in 16 day(s) on June 20, 2025. This event was a transfer of 750 contract(s) at a $18.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.4K, with a price of $34.0 per contract. There were 49987 open contracts at this strike prior to today, and today 898 contract(s) were bought and sold. 
• Regarding SRDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>), we observe a call option trade with bullish sentiment. It expires in 72 day(s) on August 15, 2025. Parties traded 500 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $190.0K, with a price of $380.0 per contract. There were 502 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bullish sentiment. It expires in 44 day(s) on July 18, 2025. Parties traded 38 contract(s) at a $310.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $43.5K, with a price of $1145.0 per contract. There were 3038 open contracts at this strike prior to today, and today 494 contract(s) were bought and sold. 
• Regarding AKBA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), we observe a call option trade with bullish sentiment. It expires in 226 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $2.50 strike. The total cost received by the writing party (or parties) was $31.0K, with a price of $155.0 per contract. There were 438 open contracts at this strike prior to today, and today 350 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $88.3K, with a price of $883.0 per contract. There were 576 open contracts at this strike prior to today, and today 217 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bullish, expiring in 198 day(s) on December 19, 2025. This event was a transfer of 5 contract(s) at a $710.00 strike. The total cost received by the writing party (or parties) was $63.4K, with a price of $12690.0 per contract. There were 25 open contracts at this strike prior to today, and today 13 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be neutral, expiring in 226 day(s) on January 16, 2026. This event was a transfer of 10 contract(s) at a $115.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $87.5K, with a price of $8753.0 per contract. There were 12 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be neutral, expiring in 471 day(s) on September 18, 2026. This event was a transfer of 5 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $35.6K, with a price of $7130.0 per contract. There were 0 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AKBA

NTRA

SRDX

TEVA

9 Health Care Stocks Whale Activity In Today's Session

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/05/30/final-trades-jpmorgan-meta-abbvie-and-gap.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown, CEO of Ritholtz Wealth Management, said he is staying long on JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), adding that the company has the greatest <a href="https://www.benzinga.com/quote/JPM">CEO ever in banking</a>.
Supporting his views, several analysts, including, Baird, Morgan Stanley, RBC Capital, Piper Sandler and TD Securities, raised their price targets on the stock on May 20.
Kevin Simpson, Capital Wealth Planning CIO, said Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has tons of free cash flow.
As per recent news, Meta and Palmer Luckey-led defense tech startup Anduril Industries announced a partnership to develop rugged VR/AR headsets for the U.S. Army on May 29.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Jim Lebenthal of Cerity Partners named AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) as his final trade.
On May 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to AbbVie's Emrelis (telisotuzumab vedotin-tllv) for adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy.
Stephanie Link, Hightower chief investment strategist, picked The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) as her final trade.
Supporting her view, Gap reported quarterly earnings of 51 cents per share on May 29, beating the consensus estimate of 45 cents. Quarterly revenue came in at $3.46 billion, beating the Street estimate of $3.42 billion.
Price Action:
<ul class="wp-block-list">
<li>JPMorgan shares fell 0.1% to close at $264.00 on Friday.</li>
<li>Meta gained 0.4% to close at $647.49 on Friday.</li>
<li>AbbVie shares rose 0.3% to settle at $186.11 during the session.</li>
<li>Gap shares dipped 20.2% to close at $22.31 on Friday.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo: Shutterstock

Meta, JPMorgan, Gap And A Health Care Stock On CNBC's 'Final Trades'

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$55.00</td>
<td>$71.1K</td>
<td>2.1K</td>
<td>1.3K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$25.00</td>
<td>$68.0K</td>
<td>2.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$100.00</td>
<td>$44.0K</td>
<td>1.1K</td>
<td>960</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$630.00</td>
<td>$119.6K</td>
<td>6</td>
<td>705</td>
</tr>
<tr>
<td>VEEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$210.00</td>
<td>$65.7K</td>
<td>534</td>
<td>589</td>
</tr>
<tr>
<td>NVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$115.00</td>
<td>$28.0K</td>
<td>1.8K</td>
<td>379</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$80.00</td>
<td>$42.5K</td>
<td>883</td>
<td>372</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$295.00</td>
<td>$40.2K</td>
<td>985</td>
<td>344</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$195.00</td>
<td>$25.8K</td>
<td>5.0K</td>
<td>319</td>
</tr>
<tr>
<td>COR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$280.00</td>
<td>$36.4K</td>
<td>762</td>
<td>200</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a put option sweep that happens to be bearish, expiring in 51 day(s) on July 18, 2025. This event was a transfer of 89 contract(s) at a $55.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $71.1K, with a price of $799.0 per contract. There were 2196 open contracts at this strike prior to today, and today 1320 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 9 day(s) on June 6, 2025. This event was a transfer of 1000 contract(s) at a $25.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $68.0K, with a price of $68.0 per contract. There were 2289 open contracts at this strike prior to today, and today 1083 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a put option trade that happens to be bearish, expiring in 9 day(s) on June 6, 2025. This event was a transfer of 958 contract(s) at a $100.00 strike. The total cost received by the writing party (or parties) was $44.0K, with a price of $46.0 per contract. There were 1139 open contracts at this strike prior to today, and today 960 contract(s) were bought and sold. 
• Regarding REGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), we observe a call option trade with neutral sentiment. It expires in 51 day(s) on July 18, 2025. Parties traded 46 contract(s) at a $630.00 strike. The total cost received by the writing party (or parties) was $119.6K, with a price of $2600.0 per contract. There were 6 open contracts at this strike prior to today, and today 705 contract(s) were bought and sold. 
• Regarding VEEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), we observe a put option sweep with bearish sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 212 contract(s) at a $210.00 strike. This particular put needed to be split into 45 different trades to become filled. The total cost received by the writing party (or parties) was $65.7K, with a price of $310.0 per contract. There were 534 open contracts at this strike prior to today, and today 589 contract(s) were bought and sold. 
• For NVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), we notice a call option sweep that happens to be bullish, expiring in 23 day(s) on June 20, 2025. This event was a transfer of 224 contract(s) at a $115.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $125.0 per contract. There were 1879 open contracts at this strike prior to today, and today 379 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a call option trade that happens to be bearish, expiring in 79 day(s) on August 15, 2025. This event was a transfer of 100 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $42.5K, with a price of $425.0 per contract. There were 883 open contracts at this strike prior to today, and today 372 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option trade with bullish sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 134 contract(s) at a $295.00 strike. The total cost received by the writing party (or parties) was $40.2K, with a price of $300.0 per contract. There were 985 open contracts at this strike prior to today, and today 344 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be bullish, expiring in 23 day(s) on June 20, 2025. This event was a transfer of 137 contract(s) at a $195.00 strike. The total cost received by the writing party (or parties) was $25.8K, with a price of $189.0 per contract. There were 5038 open contracts at this strike prior to today, and today 319 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a put option sweep with neutral sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 135 contract(s) at a $280.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $36.4K, with a price of $270.0 per contract. There were 762 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GILD

VEEV

10 Health Care Stocks Whale Activity In Today's Session

Today, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.scri.com%2F&amp;esheet=54261017&amp;newsitemid=20250528690522&amp;lan=en-US&amp;anchor=Sarah+Cannon+Research+Institute+%28SCRI%29&amp;index=1&amp;md5=89e1c577df921146fbc6b00973e49a5c">Sarah Cannon Research Institute (SCRI)</a>, one of the world's leading oncology research organizations conducting community-based clinical trials, announced a strategic alliance with AbbVie. The alliance aims to accelerate the development of innovative therapies for patients with cancer through collaborative scientific engagement and operational synergies to enhance the delivery of clinical trials.
 &nbsp;

Sarah Cannon Research Institute Announces Strategic Alliance With AbbVie To Advance Cancer Therapies

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/30/25</td>
<td>$65.00</td>
<td>$37.4K</td>
<td>872</td>
<td>1.6K</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$70.00</td>
<td>$302.0K</td>
<td>5.1K</td>
<td>1.1K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$850.00</td>
<td>$33.5K</td>
<td>31.4K</td>
<td>798</td>
</tr>
<tr>
<td>VERA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$30.00</td>
<td>$41.1K</td>
<td>446</td>
<td>342</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$400.00</td>
<td>$33.4K</td>
<td>1.9K</td>
<td>282</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$65.00</td>
<td>$104.7K</td>
<td>114</td>
<td>162</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$180.00</td>
<td>$111.8K</td>
<td>2.1K</td>
<td>105</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$215.00</td>
<td>$54.2K</td>
<td>385</td>
<td>87</td>
</tr>
<tr>
<td>VRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$80.00</td>
<td>$28.8K</td>
<td>50</td>
<td>40</td>
</tr>
<tr>
<td>ONC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$220.00</td>
<td>$32.2K</td>
<td>0</td>
<td>15</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a put option trade with neutral sentiment. It expires in 3 day(s) on May 30, 2025. Parties traded 170 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $37.4K, with a price of $220.0 per contract. There were 872 open contracts at this strike prior to today, and today 1645 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a put option trade that happens to be bearish, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 1000 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $302.0K, with a price of $302.0 per contract. There were 5187 open contracts at this strike prior to today, and today 1108 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $850.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $33.5K, with a price of $335.0 per contract. There were 31403 open contracts at this strike prior to today, and today 798 contract(s) were bought and sold. 
• For VERA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>), we notice a put option sweep that happens to be bullish, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 34 contract(s) at a $30.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $41.1K, with a price of $1210.0 per contract. There were 446 open contracts at this strike prior to today, and today 342 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be bullish, expiring in 598 day(s) on January 15, 2027. This event was a transfer of 10 contract(s) at a $400.00 strike. The total cost received by the writing party (or parties) was $33.4K, with a price of $3342.0 per contract. There were 1906 open contracts at this strike prior to today, and today 282 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a put option sweep that happens to be bullish, expiring in 570 day(s) on December 18, 2026. This event was a transfer of 161 contract(s) at a $65.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $104.7K, with a price of $655.0 per contract. There were 114 open contracts at this strike prior to today, and today 162 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option trade with bearish sentiment. It expires in 80 day(s) on August 15, 2025. Parties traded 87 contract(s) at a $180.00 strike. The total cost received by the writing party (or parties) was $111.8K, with a price of $1286.0 per contract. There were 2152 open contracts at this strike prior to today, and today 105 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a put option sweep with bullish sentiment. It expires in 24 day(s) on June 20, 2025. Parties traded 67 contract(s) at a $215.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $54.2K, with a price of $810.0 per contract. There were 385 open contracts at this strike prior to today, and today 87 contract(s) were bought and sold. 
• For VRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 40 contract(s) at a $80.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $28.8K, with a price of $720.0 per contract. There were 50 open contracts at this strike prior to today, and today 40 contract(s) were bought and sold. 
• For ONC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>), we notice a call option trade that happens to be neutral, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 15 contract(s) at a $220.00 strike. The total cost received by the writing party (or parties) was $32.2K, with a price of $2150.0 per contract. There were 0 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VERA

VRNA

AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock is trending on Tuesday after the U.S. drug giant announced that key data from its broad oncology portfolio will be showcased at the upcoming American Society of Clinical <a href="https://www.benzinga.com/pressreleases/25/05/n45616821/abbvie-features-new-data-across-difficult-to-treat-solid-tumors-and-blood-cancers-at-asco-2025-hig" target="_blank" rel="noreferrer noopener">Oncology (ASCO) Annual Meeting</a>.
An oral presentation on investigational&nbsp;elotuzumab adizutecan (ABBV-400, Temab-A), a next-generation, c-Met directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">payload, will showcase</a>:
<ul class="wp-block-list">
<li>Preliminary safety and efficacy results from the dose expansion part of a Phase 1 study in 41 patients with pre-treated, advanced epidermal growth factor receptor (EGFR)-mutated non-squamous non-small cell lung cancer (NSCLC).</li>
<li>The objective response rate (ORR) was 63%. High ORR was observed regardless of c-Met protein expression levels.</li>
<li>At the time of data cut-off, 54% of responders experienced a ≥6 months duration of response (DoR).</li>
<li>Temab-A is also being evaluated in multiple ongoing&nbsp;clinical trials, including: 
<ul class="wp-block-list">
<li>Phase 1/2 Study in first-line NSCLC without actionable&nbsp;genomic alterations in combination with budigalimab.</li>
<li>Phase 2 study in second-line metastatic colorectal cancer (CRC) in combination with fluorouracil, folinic acid, and bevacizumab.</li>
<li>Phase 3 study as monotherapy in patients with c-Met overexpressing refractory metastatic&nbsp;CRC.</li>
</ul>
</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45418687/fda-fast-tracks-abbvies-new-lung-cancer-therapy-emrelis-for-tough-lung-cancer-cases" rel="noreferrer noopener">FDA Fast-Tracks AbbVie&#8217;s New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases</a>
Additional oral presentations will highlight new safety and efficacy data for ABBV-706, a SEZ6-directed ADC with a Top1i payload, and pivekimab sunirine&nbsp;(PVEK), a novel ADC designed to target CD123:
<ul class="wp-block-list">
<li>In a Phase 1 open-label study of ABBV-706 monotherapy, 64 patients received ABBV-706 monotherapy IV at 1.3–3.5 mg/kg once every 3 weeks.</li>
<li>The entire cohort had an ORR of 31.3% and a median DoR of 5.6 months.</li>
<li>This ongoing study is evaluating ABBV-706 as monotherapy or in combination with budigalimab, carboplatin, or cisplatin in patients with advanced solid tumors expressing SEZ6, including small-cell lung cancer, NENs, and high-grade Central Nervous System tumors.</li>
</ul>
Results from the open-label, multicenter Phase&nbsp;1b/2 CADENZA trial of PVEK monotherapy in patients with previously untreated or relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN), a highly aggressive and rare type of blood cancer, demonstrated clinical benefit.
<ul class="wp-block-list">
<li>The results show that among 33 untreated patients, the primary endpoint of composite complete response (CCR) rate, defined as CR + clinical CR (CR with minimal skin abnormality), was 70%, with a median duration of CCR of 9.8 months.</li>
<li>ORR was 85%.</li>
<li>In the 51 patients, the CCR rate was 14%, with a median duration of CCR of 9.2 months. ORR was 35%.</li>
<li>PVEK is also being evaluated in a Phase 1/2 study in R/R and newly diagnosed acute myeloid leukemia.</li>
</ul>
Price Action: At the last check on Tuesday, ABBV stock was up 1.11% at $185.29 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45616623/temu-parent-pdd-does-not-mention-tariffs-impact-blames-external-environment-and-ecosystem-investments-for-profit-plunge" target="_blank" rel="noreferrer noopener">Temu Parent PDD Does Not Mention Tariffs Impact, Blames &#8216;External Environment&#8217; And &#8216;Ecosystem Investments&#8217; For Profit Plunge</a></li>
</ul>
Image: Shtutterstock

AbbVie To Present Cancer Trial Data At Upcoming ASCO Event

-&nbsp; &nbsp;&nbsp;Key oral presentations highlight new data from AbbVie's novel investigational antibody-drug conjugates (ADCs) including telisotuzumab adizutecan (ABBV-400, Temab-A) in advanced non-small cell lung cancer (NSCLC), ABBV-706 in high-grade neuroendocrine neoplasms (NENs) and pivekimab sunirine (PVEK) in blastic plasmacytoid dendritic cell neoplasm (BPDCN).
NORTH CHICAGO, Ill., May 27, 2025 /PRNewswire/ -- AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) today announced that key data from its broad oncology portfolio will be showcased across multiple oral presentations and posters at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3, 2025). These new data highlight significant progress in AbbVie's robust oncology pipeline, across a range of difficult-to-treat solid tumors and blood cancers.

AbbVie Says Key Data From Broad Oncology Portfolio To Be Showcased Across Multiple Oral Presentations And Posters At 2025 ASCO Annual Meeting

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$90.00</td>
<td>$286.6K</td>
<td>20.5K</td>
<td>19.1K</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$320.00</td>
<td>$82.5K</td>
<td>2.3K</td>
<td>5.2K</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$290.00</td>
<td>$330.7K</td>
<td>64</td>
<td>1.3K</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$50.00</td>
<td>$81.0K</td>
<td>573</td>
<td>292</td>
</tr>
<tr>
<td>OCUL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$10.00</td>
<td>$32.5K</td>
<td>60</td>
<td>190</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/27/25</td>
<td>$810.00</td>
<td>$35.5K</td>
<td>12</td>
<td>169</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$45.00</td>
<td>$43.0K</td>
<td>3.5K</td>
<td>113</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$60.00</td>
<td>$35.0K</td>
<td>2.4K</td>
<td>85</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$175.00</td>
<td>$93.8K</td>
<td>384</td>
<td>59</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$40.00</td>
<td>$29.9K</td>
<td>776</td>
<td>58</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a put option trade that happens to be bearish, expiring in 31 day(s) on June 20, 2025. This event was a transfer of 11467 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $286.6K, with a price of $25.0 per contract. There were 20532 open contracts at this strike prior to today, and today 19153 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option trade with bearish sentiment. It expires in 10 day(s) on May 30, 2025. Parties traded 60 contract(s) at a $320.00 strike. The total cost received by the writing party (or parties) was $82.5K, with a price of $1375.0 per contract. There were 2315 open contracts at this strike prior to today, and today 5276 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option trade with bullish sentiment. It expires in 10 day(s) on May 30, 2025. Parties traded 1350 contract(s) at a $290.00 strike. The total cost received by the writing party (or parties) was $330.7K, with a price of $245.0 per contract. There were 64 open contracts at this strike prior to today, and today 1371 contract(s) were bought and sold. 
• Regarding AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we observe a call option sweep with bullish sentiment. It expires in 31 day(s) on June 20, 2025. Parties traded 270 contract(s) at a $50.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $81.0K, with a price of $300.0 per contract. There were 573 open contracts at this strike prior to today, and today 292 contract(s) were bought and sold. 
• Regarding OCUL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>), we observe a put option trade with bearish sentiment. It expires in 213 day(s) on December 19, 2025. Parties traded 100 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $32.5K, with a price of $325.0 per contract. There were 60 open contracts at this strike prior to today, and today 190 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bearish, expiring in 38 day(s) on June 27, 2025. This event was a transfer of 24 contract(s) at a $810.00 strike. The total cost received by the writing party (or parties) was $35.5K, with a price of $1480.0 per contract. There were 12 open contracts at this strike prior to today, and today 169 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a put option trade with bearish sentiment. It expires in 304 day(s) on March 20, 2026. Parties traded 104 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $43.0K, with a price of $414.0 per contract. There were 3563 open contracts at this strike prior to today, and today 113 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with neutral sentiment. It expires in 87 day(s) on August 15, 2025. Parties traded 25 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $1400.0 per contract. There were 2475 open contracts at this strike prior to today, and today 85 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bearish sentiment. It expires in 87 day(s) on August 15, 2025. Parties traded 59 contract(s) at a $175.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $93.8K, with a price of $1590.0 per contract. There were 384 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be bullish, expiring in 605 day(s) on January 15, 2027. This event was a transfer of 9 contract(s) at a $40.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $29.9K, with a price of $3330.0 per contract. There were 776 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKRO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

OCUL

10 Health Care Stocks With Whale Alerts In Today's Session

Press Releases

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV

AbbVie Partners with Chicago Cubs on "Striking Out Cancer"

Legal

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join – Contact Levi & Korsinsky

AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals

Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc. (ABBV)

U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes

AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention

Dividends

AbbVie Declares Quarterly Dividend

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Citigroup

Guggenheim

Raymond James

Evercore ISI Group

Morgan Stanley

Screenshot 2024-11-13 at 11.54.41 PM

TNXP

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-05-14 at 6.27.53 PM

BRTX

CYNO

BioRestorative Therapies (NASDAQ: BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

Screenshot 2024-02-24 at 12.03.42 AM

AXSM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

5월 12일, 도널드 트럼프 대통령은 제약사들이 미국 내 처방약 가격을 해외 수준으로 낮추도록 하는 행정명령(EO)에 서명함으로써 선거 공약을 이행했다.
한 미디어 행사에서 트럼프 대통령은 기자들에게 59%에서 90% 사이의 가격 인하를 목표로 하고 있다고 말하며 제약사들에게 30일의 시간을 주었다. 월가는 이 소식을 받아들였고, 행정명령이 발표된 날 주요 바이오제약 주식의 주가는 하락했지만 대부분의 업계 주식은 반등했다.
트럼프의 행정명령으로 인해 반등에 그치지 않고 급등할 것으로 예상되는 제약주 3가지를 소개한다.
<h3 class="wp-block-heading">트럼프 팀의 탄탄한 논리?</h3>
미국의 약값이 과도하다는 사실은 누구도 부인하지 않는다. 2024년 RAND 코퍼레이션의 연구에 따르면 미국의 약값은 다른 33개 선진국의 약값보다 약 3배 높다고 한다.
미국 대통령은 적어도 부분적으로는 민간 업계에 가격 인하를 명령할 수 있는 전권을 가지고 있다.
플로리다주 팜비치 가든에 위치한 베스트 프랙티스 인스티튜트(Best Practice Institute)의 설립자 겸 CEO인 루 카터(Lou Carter)는 "특히 메디케어와 같은 정부 프로그램이 대규모 구매자인 의료 분야에서는 더욱 그렇다&#8221;고 한다. "정책은 단순히 법에 관한 것이 아니라 영향력에 관한 것이다. 이번 행정명령은 공공 프로그램의 무게를 이용해 가격 책정의 책임을 강제하는 것으로, 납세자 자금을 관리할 때 현명한 비즈니스다.&#8221;
의회와 법원은 행정명령을 저지하기 위해 노력할 수 있지만 성공 가능성은 희박하다.
카터는 "정치적으로 약가 인하에 반대하기는 어렵다&#8221;고 했다. "제약사가 열심히 로비를 하더라도 대부분의 의원들은 노인들이 인슐린을 구입할 수 있도록 도와주는 것에 반대하는 것이 정치적 자살 행위라는 것을 알고 있다. 만약 이 문제가 법정으로 간다면, 이러한 조치가 대중적인지 옳은지 여부가 아니라 절차상의 문제에 달려 있을 것이다.&#8221;
<h3 class="wp-block-heading">대형 제약사에 가장 큰 타격</h3>
행정명령의 규모와 범위를 고려할 때, 규모가 큰 제약사일수록 재정적 어려움에 처할 수 있다는 것은 놀라운 일이 아니다.
뉴욕시에 본사를 둔 의료업무 인증위원회(Accreditation Council for Medical Affairs)의 설립자 겸 CEO인 윌 솔리먼 박사는 "암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)이나 리제네론(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)처럼 메디케어에 많이 노출된 대형 바이오테크 및 전문 제약회사가 가장 큰 타격을 받을 수 있다&#8221;고 한다.&#8221;그들은 수익성이 높은 (메디케어) 파트 B 의약품에 의존하고 있다."
파이프라인이 좁은 제약사들도 행정명령으로 인해 타격을 입을 수 있다.
메릴랜드주 베데스다에 위치한 말로이(Malloy) 법률 사무소의 설립자이자 대표 파트너인 션 말로이(Seann Malloy)는 "브리스톨 마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) 같은 전문 항암제 제조업체는 광범위한 포트폴리오를 보유한 다각화된 제약 회사보다 더 큰 영향을 받을 수 있다&#8221;고 했다. "초기 상용 제품을 보유한 중소형 생명공학 기업은 제한된 메디케어 활용과 기존 가격 보호 조항으로 인해 즉각적인 영향권에서 벗어나는 경우가 많다.&#8221;
"행정 명령의 핵심 요소는 메디케어의 처방약 지급이 다른 선진국의 최저 가격과 일치하도록 의무화하는 것으로, 기본적으로 국제 참조 가격을 사용한다. 일부 시범 프로젝트는 30일 이내에 시작되지만 필요한 규정 개발로 인해 모든 조항을 완전히 시행하는 데는 6~12개월이 더 걸릴 것이다.&#8221;
한편, 해당 행정명령이 생명공학 의약품 주식에 얼마나 큰 영향을 미칠지 결정하는 데는 시기가 중요한 역할을 할 수 있다.
처음에는 이러한 행정명령이 메디케어 파트 B에 따른 의사가 투여하는 의약품에 초점을 맞추지만, 나중에 파트 D에 따른 소매 처방도 포함될 수 있다. 말로이는 이렇게 말했다. "이러한 단계적 시행은 즉각적인 시장 효과와 장기적인 시장 효과가 다를 것이라는 것을 의미하며, 투자자들이 종종 놓치는 점이다. 초기에는 가격이 빠르게 변화할 것으로 보이지만, 광범위한 규제 절차로 인해 상당한 매출 영향이 지연될 가능성이 높다."
또한 해외 의약품 공급업체는 트럼프 약가 지침으로 인해 거센 역풍을 맞을 수도 있다.
미국 히스패닉 비즈니스 위원회(United States Hispanic Business Council)의 설립자 겸 CEO인 하비에르 팔로마레즈(Javier Palomarez)는 "해외 제조업체가 가장 취약하다&#8221;며 &#8220;이들 중 상당수는 투자 수익률 때문에 미국으로 의약품을 출하하는데, 이러한 수익률이 약화되면 전 세계로 의약품을 출하할 인센티브와 능력이 약화되어 일부 기업의 경우 미국 시장 접근성이 완전히 상실될 수 있다&#8221;고 했다.
<h3 class="wp-block-heading">향후 30일간 주의 깊게 지켜봐야 할 제약주 3가지</h3>
트럼프의 행정명령을 활용하고자 하는 바이오테크 투자자들은 트럼프가 5월 12일 기자회견에서 말한 것처럼 "중개인을 없애겠다"는 트럼프의 의도를 이해해야 한다. 이는 실제 의약품 제조업체에게는 좋은 소식이지만 소위 처방약급여관리업체(PBM)에게는 좋지 않은 소식으로 해석될 수 있다.
PBM은 건강 보험 회사, 대형 고용주, 제약 제조업체, 보험사, 환자 사이의 중개자 역할을 한다. 처방약을 생산하지는 않지만 청구 처리 및 처방약 가격 협상과 같은 의약품 비즈니스의 일상적인 측면을 처리한다.
대형 제약사들은 역사적으로 높은 약값에 대해 PBM을 비난해 왔으며, 소비자 직접 판매 의약품 시장을 확대하는 모든 이니셔티브를 지지할 가능성이 높다. 이 시나리오에서는 의약품 소비자가 제약회사와 직접 거래하여 필요한 의약품을 더 저렴한 가격에 구매할 수 있기 때문에 보험사가 필요하지 않다.
이 시장의 투자자들은 대형 제약사를 원할 것이고, 대형 PBM은 원하지 않을 것이다. 따라서 다음 제약주 3가지는 긍정적인 측면이 두드러진다.
<h4 class="wp-block-heading">일라이 릴리</h4>
의약품 제조 대기업 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) 주가는 주당 730달러로 높지만, 소비자 직접 처방약 시장에서 번창할 가능성이 높은 주식이다. 주가는 연초 대비 5.0% 하락했지만, 일라이 릴리를 추적하는 26명의 월스트리트 애널리스트가 최고 등급을 부여했다. 회사의 최근 주당순이익은 차트에서 벗어났으며, 2024년 주당 순이익은 106%, 2025년에는 68%까지 상승할 것으로 예상된다. 주가는 최근 고점 대비 20% 할인된 상태이며, 이는 제약 업계의 견실한 기업에게는 좋은 할인이 될 수 있다.
<h4 class="wp-block-heading">노보 노디스크</h4>
노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)는 수익성이 좋은 체중 감량 치료제 시장에서 경쟁사들이 계속해서 시장 점유율을 잠식하면서 트럼프의 행정명령 이전부터 시장의 어려움을 겪어 왔다. 특히 최근 일라이 릴리의 젭바운드(Zepbound: 마운자로와 동일)를 복용한 환자가 노보 노디스크의 위고비(Wegovy)보다 더 빨리 체중이 감소한다는 결론을 내린 연구 결과가 큰 타격을 입혔다. 이것이 바로 지난 한 해 동안 노보 노디스크의 주가가 50% 하락한 가장 큰 이유 중 하나다.
그러나 현재 주가는 지난 한 달 동안 13.9% 상승하며 반등 모드에 있다. 체중 감량 약물을 개발하기 위한 노보 노디스크와 셉테르나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) 간 22억 달러 규모의 거래는 애널리스트들이 큰 진전을 이루었다고 평가하며, 골드만삭스와 JP 모건과 같은 대형 기업들은 노보 노디스크에 대한 매수 의견을 고수하고 있다. 그리고 더 많은 업계 애널리스트들이 현재 수준에서 50%의 주가 상승 여력을 가진다는 컨센서스에 도달했다.
<h4 class="wp-block-heading">애브비</h4>
애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)는 보톡스(Botox), 휴미라(Humira), 린보크(Rinvoq), 스카이리치(Skyrizi) 등 다양한 인기 처방약을 생산하는 제약사로 워싱턴 DC의 정치적 간섭에 영향을 받지 않는 진정한 현금 흐름 창출 기업이다. 이번 주 행정명령 뉴스에서 주가는 1%밖에 하락하지 않았고, 지난 한 달 동안 5% 상승했다. 또한 소득을 중시하는 투자자를 위한 3.6%의 배당금, 탄탄한 의약품 파이프라인, 폐암 치료제 엠렐리스(Emrelis)에 대한 새로운 규제 &#8216;청신호&#8216;가 제공되어 2025년에도 애브비 주가가 계속 상승할 것이라는 근거를 뒷받침하고 있다.
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)는 10년래 최저 밸류에이션에 가까운 거래에도 불구하고, 특히 씨젠 인수를 통해 종양학 혁신을 통해 장기적인 성장을 위해 전략적으로 재편하고 있다. 시장은 여전히 코로나19 관련 매출 감소와 다가오는 특허 절벽에 집착하고 있지만, 투자자들은 회사의 극적으로 확장된 종양학 파이프라인, 탄탄한 잉여현금흐름, 2025~2026년에 상당한 주가 상승을 이끌 수 있는 여러 촉매제의 잠재력을 간과하고 있다.
<h3 class="wp-block-heading"><a>핵심 포인트</a></h3>
<ol>
<li>화이자의 현재 가치 평가 지표는 장기적인 성장 잠재력과 현저한 괴리를 드러낸다.</li>
<li>430억 달러 규모의 씨젠(Seagen) 인수는 화이자의 항암제 파이프라인을 근본적으로 변화시켰다.</li>
<li>단기적인 매출 압박에도 불구하고 화이자의 재무 상태는 다양한 성장 경로를 통해 견고한 상태를 유지하고 있다.</li>
<li>주요 경쟁사와 비교한 결과 화이자는 현재 가격에서 매력적인 위험 대비 보상을 제공한다.</li>
<li>2025~2026년에 예정된 촉매제로 인해 상당한 재평가가 이루어질 수 있다.</li>
</ol>
<h3 class="wp-block-heading"><a>서론: 영광의 추락</a></h3>
화이자만큼 급격한 주가 하락을 경험한 거대 제약회사는 거의 없다. 2021~2022년 코로나19 백신과 항바이러스 치료제의 성공으로 고공행진을 이어가던 화이자의 주가는 2021년 12월 최고가인 52.61달러에서 60% 이상 급락했다. 현재 약 23.87달러인 화이자의 주가수익비율은 7.41배에 불과하며, 이는 일반적으로 세계 최고의 제약 혁신 기업이라기보다는 존립 위협에 직면한 기업에서나 볼 수 있는 수준이다.
화이자를 둘러싼 시장의 이야기는 압도적으로 부정적이다. 주로 다음과 같은 내용에 집중하고 있다.
<ol class="wp-block-list">
<li>COVID-19 제품 수익의 급격한 감소</li>
<li>인리타(Inlyta, 2025)와 엑스탄디(Xtandi, 2027)와 같은 주요 약물의 다가오는 특허 만료</li>
<li>체중 감소와 같은 분야에서의 미진한 파이프라인 개발</li>
<li>430억 달러 규모의 씨젠 인수에 대한 투자 수익률에 대한 우려</li>
</ol>
이러한 비관적인 전망은 오늘날 제약 부문에서 가장 매력적인 투자 기회 중 하나라고 생각한다. 시장은 화이자의 전략적 변화와 확장된 항암제 포트폴리오의 잠재력을 크게 저평가하고 있다.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" class="wp-image-12977" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15031106/image-3.png" sizes="(max-width: 975px) 100vw, 975px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15031106/image-3.png 975w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15031106/image-3-300x187.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15031106/image-3-768x480.png 768w" alt="" width="975" height="609" /></figure>
<h3 class="wp-block-heading">평가 불일치: 시장의 과잉 반응</h3>
화이자의 현재 평가 지표는 시장의 과잉 반응을 강력하게 나타낸다.
<ul class="wp-block-list">
<li>P/E 비율: 7.41배 (업종 평균 ~15배)</li>
<li>선행 P/E: 8.0배 (2025년 가이던스 기준)</li>
<li>배당수익률: 7.20% (역사적 평균보다 상당히 높음)</li>
<li>시가총액: 1,353억 8천만 달러 (정점에서 3,000억 달러 이상에서 하락)</li>
</ul>
화이자와 같은 수준의 회사가 이러한 밸류에이션 수준에서 거래된다는 것은 시장이 비즈니스 펀더멘털의 영구적인 악화를 정확하게 예상하고 있거나, 아니면 반대 투자자들에게 상당한 기회를 제공하고 있다는 뜻이다. 나는 후자라고 생각한다.
화이자의 매출과 이익은 COVID-19 제품 수요의 정상화 이후 급격히 감소했지만, 회사의 2025년 가이던스는 안정성이 다가오고 있음을 시사한다. 2025년 화이자는 다음을 예상하고 있다.
<ul class="wp-block-list">
<li>매출 61~64억 달러</li>
<li>조정 주당순이익(EPS) 2.80-3.00 달러</li>
<li>비일회성 COVID 수익을 제외한 운영 매출 성장률 0~5%</li>
</ul>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" class="wp-image-12979" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033015/image-4.png" sizes="(max-width: 975px) 100vw, 975px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033015/image-4.png 975w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033015/image-4-300x187.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033015/image-4-768x480.png 768w" alt="" width="975" height="609" /></figure>
이러한 전망은 비록 화려하지 않지만, 일반적으로 정체기에 있는 기업에 해당하는 평가를 정당화하기에는 부족하다. 더 중요한 것은, 이것이 화이자의 종양학 변혁이 미래 성장을 이끌 수 있는 안정적인 기반을 제공한다는 것이다.
<h3 class="wp-block-heading"><a>씨젠 인수: 파이프라인 혁신</a></h3>
2023년 12월, 화이자는 430억 달러 규모의 씨젠 인수를 완료하여 회사의 항암제 포트폴리오를 근본적으로 변화시켰다. 이 인수는 단순히 매출 증대에 그치지 않고 화이자의 초기 단계 항암제 파이프라인을 두 배로 늘리고 오늘날 암 치료에서 가장 유망한 접근법 중 하나인 항체&#8211;약물 접합체(ADC) 기술의 선두주자로 자리매김하는 전략적 전환점이 되었다.
씨젠 인수는 즉각적이고 장기적인 혜택을 가져왔다.
즉각적인 포트폴리오 강화
<ul class="wp-block-list">
<li>FDA 승인을 받은 네 가지 암 치료제(아드세트리스(Adcetris), 파드세브(Padcev), 티브닥(Tivdak), 그리고 투키사(Tukysa))</li>
<li>2023년 약 22억 달러의 총 매출</li>
<li>화이자 측은 이 약물이 2030년까지 100억 달러 이상의 위험 조정 매출에 기여할 것으로 예상</li>
</ul>
파이프라인 혁신
<ul class="wp-block-list">
<li>화이자의 종양학 파이프라인 프로그램, 60개로 두 배 증가 </li>
<li>ADC 기술 플랫폼 확장</li>
<li>블록버스터 잠재력이 있는 여러 후기 단계 파이프라인 후보 추가</li>
</ul>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" class="wp-image-12980" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033102/image-5.png" sizes="(max-width: 975px) 100vw, 975px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033102/image-5.png 975w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033102/image-5-300x187.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033102/image-5-768x480.png 768w" alt="" width="975" height="609" /></figure>
이번 인수는 절박함에서 비롯된 것이 아니라 전략적 선견지명에서 비롯된 것이다. 씨젠이 개척한 ADC 기술은 건강한 조직은 살리면서 암세포를 보다 정밀하게 표적화할 수 있게 해 준다. 이 접근법은 점점 더 암 치료의 미래로 여겨지고 있으며, 전 세계 ADC 시장은 2030년까지 연평균 10% 이상의 성장률을 보일 것으로 예상된다.
화이자 CEO인 앨버트 불라(Albert Bourla)는 "우리는 황금알을 낳는 거위를 인수하는 것이지 황금알을 인수하는 것이 아니다&#8221;라고 언급한 것은 전략적 이유를 완벽하게 포착하고 있다. 장기적인 가치는 현재의 제품뿐만 아니라 씨젠의 혁신 엔진에 있다.
<h3 class="wp-block-heading"><a>역풍에도 불구하고 재무적 강점 있어</a></h3>
단기 매출 압박이 실제로 존재하지만, 화이자의 재무 상태는 놀라울 정도로 강력하다. 
2025년 1분기 실적
<ul class="wp-block-list">
<li>매출 137억 2천만 달러</li>
<li>조정된 주당순이익(EPS) 0.92달러 (분석가 예상치인 0.66달러를 크게 웃도는 수치)</li>
<li>외부 어려움에도 연간 가이던스 유지</li>
</ul>
재무제표의 강점
<ul class="wp-block-list">
<li>상당한 현금 흐름 생성</li>
<li>배당금이 이익으로 충분히 커버됨</li>
<li>2027년까지 77억 달러의 비용 절감을 목표로 한 지속적인 비용 최적화</li>
</ul>
2025년 1분기 실적 발표에서 화이자 경영진은 2025년 조정된 EPS 가이던스 범위의 상단으로 &#8220;향하고 있다&#8221;고 언급하며 운영 효율성과 비용 절제가 성과를 내고 있음을 시사했다.
<h3 class="wp-block-heading"><a>경쟁 환경: 화이자의 위치</a></h3>
화이자의 투자 잠재력을 완전히 이해하기 위해 주요 경쟁자와 비교할 필요가 있다.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" class="wp-image-12981" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033126/image-6.png" sizes="(max-width: 975px) 100vw, 975px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033126/image-6.png 975w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033126/image-6-300x187.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/15033126/image-6-768x480.png 768w" alt="" width="975" height="609" /></figure>
존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)
<ul class="wp-block-list">
<li>시가총액: 약 3,950억 달러</li>
<li>P/E 비율: 약 25배</li>
<li>배당 수익률: 약 3.0%</li>
<li>성장 도전: 2025년 스텔라라(Stelara) 특허 만료 및 지속적인 탈크 소송</li>
</ul>
머크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)
<ul class="wp-block-list">
<li>시가총액: 약 2,080억 달러</li>
<li>P/E 비율: 약 16배</li>
<li>배당 수익률: 약 2.9%</li>
<li>성장 도전: 키트루다(Keytruda)에 대한 과도한 의존, 이 약물은 이번 2030년 특허 만료를 앞두고 있음</li>
</ul>
애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)
<ul class="wp-block-list">
<li>시가총액: 약 3,400억 달러</li>
<li>P/E 비율: 약 20배</li>
<li>배당 수익률: 약 3.6%</li>
<li>성장 도전: 스카이리지(Skyrizi)와 린보크(Rinvoq) 성장을 통해 휴미라(Humira) 특허 절벽 극복 중</li>
</ul>
이러한 경쟁사들에 비해 화이자는 업계 전반적으로 비슷한 도전에 직면해 있으면서도 훨씬 더 매력적인 밸류에이션 지표를 제공한다. 이러한 밸류에이션 격차는 시장에서 화이자의 성장 전망이 경쟁사보다 상당히 낮다고 보고 있다는 것을 의미하며, 이는 화이자의 파이프라인과 전략적 이니셔티브가 뒷받침하지 않는 가정이다. 
<h3 class="wp-block-heading"><a>2025~2026년 재평가 촉매</a></h3>
향후 12~24개월 동안 화이자의 재평가를 이끌 수 있는 여러 잠재적 촉매가 있다.
<ol class="wp-block-list">
<li>파이프라인 이정표: 2025-2026년에 종양학 프로그램에서 여러 후기 단계 결과가 예상되며, 특히 방광암을 위한 유망한 디시타맙 베도틴(disitamab vedotin) 프로그램의 데이터가 포함된다.</li>
<li>마진 확장: 화이자의 비용 최적화 이니셔티브는 2027년까지 77억 달러의 절감을 제공할 것으로 예상되며, 조정된 운영 마진을 높일 수 있다.</li>
<li>종양학 매출 성장: 종양학 포트폴리오, 특히 씨젠 제품은 새로운 적응증이 승인되고 상업적 실행이 개선됨에 따라 강력한 성장을 이끌 것으로 예상된다.</li>
<li>GLP-1 프로그램 발전: 화이자의 경구 GLP-1 후보인 다누글립론(danuglipron)의 진전이 회사를 급성장하는 비만 시장에 위치시킬 수 있다.</li>
<li>잠재적인 매각 또는 분사: 전략적 포트폴리오 최적화가 주주 가치를 창출할 수 있으며, 비핵심 자산의 매각이 있을 수 있다.</li>
</ol>
<h3 class="wp-block-heading"><a>투자 위험</a></h3>
어떤 투자 논의도 위험을 인정하지 않고는 완전하지 않다.
<ol class="wp-block-list">
<li>특허 절벽 압박: 화이자는 인리타(2025)와 엑스탄디(2027)의 특허 만료를 맞이하며, 이는 단기적으로 매출에 영향을 미칠 것이다.</li>
<li>씨젠 통합 도전: 씨젠 인수의 잠재력을 완전히 실현하려면 성공적인 통합과 파이프라인 실행이 필요하다.</li>
<li>약가 압박: 인플레이션 감축 법안과 잠재적인 미래의 약가 개혁이 수익성에 영향을 미칠 수 있다.</li>
<li>종양학 경쟁: 종양학 분야는 매우 경쟁이 치열하며 많은 기업이 비슷한 목표를 추구하고 있다.</li>
<li>관세 불확실성: 최근 실적 발표에서 언급했듯이 잠재적인 제약 관세는 불확실성을 야기한다.</li>
</ol>
그러나 현재 밸류에이션 수준에서는 이러한 리스크의 상당 부분이 이미 주가에 반영되어 있어 비대칭적인 위험-보상 프로파일을 형성하고 있는 것으로 보인다.
<h3>결론: 화이자의 부활 시나리오</h3>
화이자의 극적인 추락은 인내심 있는 투자자들에게 매력적인 기회를 만들어냈다. 특히 씨젠 인수를 통해 종양학으로 전략적으로 전환한 화이자는 의학계에서 가장 유망한 분야 중 하나인 종양학 분야의 선두주자로 자리매김했다. 단기적인 도전은 현실이지만, 현재의 기업 가치는 화이자의 파이프라인 잠재력과 전략적 변화를 고려하지 않은 지나치게 비관적인 시각을 반영한다.
투자 논리가 실현되기를 기다리는 동안 여러 촉매제와 상당한 수익을 제공하는 배당 수익률로 인해 화이자는 현재 제약 부문에서 가장 매력적인 위험 보상 프로필 중 하나를 제공하고 있다. 
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)의 주가가 화요일 0.59% 상승 마감했다. 주가는 상승세에 있었다. 지난주 동안, <a href="https://www.benzinga.com/25/04/45050728/abbvies-immunology-portfolio-poised-to-continue-growing-through-humira-erosion-analyst">12% 이상 상승</a>했다.
하지만 지금은 과매수 상태이다. 이는 판매자들이 시장에 진입할 수 있게 하고, 이들이 애브비 주가를 압박할 수 있다. 벤징가의 기술 분석가 팀은 이를 <a href="https://kr.benzinga.com/?s=%EC%98%A4%EB%8A%98%EC%9D%98+%EC%A3%BC%EC%8B%9D" target="_blank" rel="noopener">오늘의 주식</a>으로 선정했다.
과매수는 주식의 모멘텀을 의미한다. 대부분의 경우 주가는 정상 또는 평균 거래 범위 내에 머물러 있다. 만약 주식이 공격적으로 매수되어 이 범위를 초과하면, 트레이더들은 이를 과매수 상태라고 말할 것이다.
이는 중요한 역동성이 될 수 있다.
많은 거래 전략은 평균 회귀 개념에 기반하고 있다. 만약 어떤 것이 과매수 상태라면, 이는 하락세로의 이동을 의미한다. 일부 트레이더들은 이 이동을 예상하여 애브비를 매도할 것이다.
이로 인해 하락세에 접어들 수 있다.
추가 읽기: <a href="https://www.benzinga.com/trading-ideas/25/04/45050322/how-youll-know-the-tariff-troubles-are-over">관세 문제가 마침내 끝났을 때를 알 수 있는 방법</a>
다음 차트 하단에는 상대 강도 지수(RSI)의 두 가지 예시가 있다. 이는 모멘텀을 분석하는 데 사용되는 인기 있는 지표이다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-893227" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29110708/ABBV-1024x566.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29110708/ABBV-1024x566.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29110708/ABBV-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29110708/ABBV-768x424.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29110708/ABBV.png 1488w" alt="" width="1024" height="566" /></figure>
기본적으로 사용되는 기간은 14일이다. 이는 현재 가격이 14일 전의 가격과 비교하여 어디에 있는지를 측정한다. 이 기간 사이의 움직임은 고려하지 않는다.
14일 모멘텀은 중립적이다—오늘의 가격은 2주 전과 대체로 비슷하여 최근의 랠리를 아직 반영하지 않았다.
기간 설정을 14에서 5로 변경하면, 주식이 매우 과매수 상태임을 보여준다.
트레이더들이 사용하는 대부분의 지표는 미리 설정된 기본 설정을 가지고 있다. 때때로, 이들은 좋은 신호를 줄 수 있다.
하지만 때때로, 이 지표는 다른 설정을 사용하여 최적화할 수 있다. 최근 시장 상황을 고려할 때, 애브비의 경우 5일 RSI가 14일 RSI보다 더 효과적일 수 있다.
이번 랠리는 일시 중지되거나 심지어 종료될 수 있다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45066479/rare-bullish-signal-just-flashed-on-wall-street-will-it-power-sp-500-to-6000">월가에서 드문 강세 신호가 발생했다: S&amp;P 500을 6,000으로 끌어올릴까?</a></li>
</ul>
사진: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국 지수 선물은 <a href="https://benzinga.com/analyst-ratings/analyst-color/25/04/44988781/wall-street-rally-extends-into-third-day-whats-driving-markets-thursday" target="_blank" rel="noopener">3일 연속</a> 정규장에서 상승세를 보인 데 이어 목요일(24일) 밤에도 상승세를 이어가고 있다. 이는 기업 실적에 대한 낙관적인 전망과 무역 긴장 완화가 영향을 미친 것으로 보인다.
S&amp;P 500 선물은 0.37% 상승해 5,531포인트를 기록했으며, 나스닥 선물은 19,416포인트로 0.49% 상승했고, 마지막으로 다우 선물은 40,248포인트로 0.03% 하락하며 보합세를 보였다. 주요 3대 지수는 모두 주간 상승세를 기록했으며, 남은 거래일은 하루다.
일본 닛케이 225 지수는 금요일 아침 상승세로 개장하며 3거래일 연속 상승세를 이어갔다. 현재 1.31% 상승한 35,498.97포인트를 기록하고 있으며 이는 미국 증시 추세를 반영한 것이다. 기술주가 상승세를 이끌고 있는 반면, 엔터테인먼트, 소매, 부동산 섹터는 조정세를 보이고 있다. 일본 정부는 미국의 관세 부과로 인한 악영향을 막기 위해 <a href="https://www.benzinga.com/25/04/44999320/japans-counterpunch-to-trump-tariffs-emergency-measures-deployed-as-us-trade-talks-loom" target="_blank" rel="noopener">여러 가지 긴급대책</a>을 발표했다.
미국 달러 지수(DXY)는 0.17% 상승한 99.55로, 월요일 3년 만에 최저치인 97.96을 기록한 후 이번 주에는 0.21% 상승했다.
투자자들은 금요일 아침 소비자 심리지수 보고서를 기다리며 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), HCA 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), 에이온(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) 등 여러 기업의 실적도 주의 깊게 살펴볼 것이다.
사진 출처: Chokchai Poomichaiya, Shutterstock.com
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국 지수 선물 상승···일본 증시 및 달러 지수 역시 동반 상승 중

도널드 트럼프 대통령은 수요일(9일) 상호관세를 90일 동안 일시 중단했지만, 나중에 집무실에서 기자들과의 대화에서 제약 회사들이 관세에 직면할 것이라고 확인했다.
무슨 일 있었나: 제약주 랠리는 목요일 시장이 하락세로 전환되면서 단기간에 그쳤다. 한 기자가 트럼프 대통령에게 제약 주식에 관세를 부과할 것이냐는 질문을 하자, 트럼프 대통령은 이렇게 답했다. "그렇게 할 것이다. 왜냐하면 우리는 그들이 다시 돌아오기를 원하기 때문이다.&#8221;
"코로나19를 겪으면서 우리는 미국에서 의약품을 만들지 않는다는 사실을 깨달았다. 그래서 큰 깨달음을 얻었다.&#8221;
트럼프는 코로나19의 비상 사태를 언급하며 제약 회사들이 미국에서 의약품을 생산하기를 원한다고 말했다.
"우리는 약을 구하기 위해 중국으로 가야 했고, 다른 곳으로 가야 했고, 약을 구하지 못했다. 우리가 그들이 떠나도록 내버려 두었기 때문이다&#8230;제약 회사에 관세를 부과할 것이고, 모두 돌아오고 싶어 할 것이다.&#8221;
트럼프의 관세 확정 이후 목요일 제약주는 급락했다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>제약주</td>
<td>목요일 주가 변동</td>
<td>2025년 변동</td>
<td>지난 1년 변동</td>
</tr>
<tr>
<td>일라이 릴리 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>-4.35%</td>
<td>-7.35%</td>
<td>-5.09%</td>
</tr>
<tr>
<td>애브비 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>-3.14%</td>
<td>-2.92%</td>
<td>3.99%</td>
</tr>
<tr>
<td>브리스톨 마이어스 스퀴브 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-6.10%</td>
<td>-11.15%</td>
<td>2.73%</td>
</tr>
<tr>
<td>리제네론 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-5.26%</td>
<td>-23.60%</td>
<td>-40.63%</td>
</tr>
<tr>
<td>화이자 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.87%</td>
<td>-18.87%</td>
<td>-18.03%</td>
</tr>
<tr>
<td>길리어드 사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>-3.66%</td>
<td>10.36%</td>
<td>47.71%</td>
</tr>
<tr>
<td>머크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-5.32%</td>
<td>-21.80%</td>
<td>-38.53%</td>
</tr>
<tr>
<td>암젠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>-3.33%</td>
<td>8.54%</td>
<td>4.23%</td>
</tr>
<tr>
<td>존슨앤드본슨 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>-1.51%</td>
<td>3.24%</td>
<td>-0.07%</td>
</tr>
</tbody>
</table>
</figure>
왜 중요한가: 90일간의 상호 관세 유예에도 불구하고 10%의 글로벌 기본 관세와 125%의 중국 관세, 그리고 철강 및 알루미늄, 자동차, 자동차 부품에 대한 25%의 부문별 관세는 그대로 유지된다. 여기에 더해 트럼프 대통령은 곧 제약사에 대한 관세를 발표할 수 있음을 시사했다.
영향을 받을 수 있는 제약 산업 관련 상장지수펀드는 다음과 같다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>제약 ETF</td>
<td>2025년 변동</td>
<td>지난 1년 변동</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>-7.02%</td>
<td>-7.51%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-7.04%</td>
<td>-6.08%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-10.13%</td>
<td>-4.37%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-14.05%</td>
<td>-11.45%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>2.88%</td>
<td>0.35%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-11.54%</td>
<td>-10.18%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-41.35%</td>
<td>-43.86%</td>
</tr>
</tbody>
</table>
</figure>
가격 움직임: 목요일 하락 후 수요일 반등에 이어 나스닥 100 지수는 전고점인 22,222.61포인트보다 17.46% 하락했다. S&amp;P 500 지수는 전고점인 6,147.43포인트 대비 14.31% 하락했고, 다우존스 지수는 52주 최고치인 45,073.63포인트 대비 12.16% 하락했다.
각각 S&amp;P 500 지수와 나스닥 100 지수를 추종하는 SPDR S&amp;P 500 ETF 신탁(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)과 인베스코 QQQ 신탁 ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 목요일에 하락 마감했다. SPY는 524.58달러로 4.38% 하락했고, QQQ는 446.18달러로 4.25% 하락했다.
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

트럼프의 의약품 관세 확인...일라이릴리·애브비·리제네론·브리스톨 등 제약주 급락

애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)와 노바티스 AG(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>)가 금요일 시장 개장 전 <a href="https://www.benzinga.com/earnings" target="_blank" rel="noopener">4분기 실적</a>을 발표할 준비를 하면서 투자자들은 두 제약 대기업 주가의 기술적 분석에 주목하고 있다.
애브비는 정체된 추세에 갇혀 있는 반면, 노바티스는 더 강한 상승 모멘텀을 보이고 있다.
차트를 분석해 보겠다.
또한 읽어보기: <a href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders">RFK Jr.와 빅파마: 보건장관 후보가 약물, 보험, 트럼프 행정명령에 대한 날카로운 질문에 답변</a>
<h1 class="wp-block-heading">애브비: 중립 상태에 갇힘</h1>
애브비의 기술적 구성은 혼재된 신호를 나타다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent013025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-758712" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131850/Screenshot-2025-01-30-at-11.40.39-PM.png" sizes="(max-width: 626px) 100vw, 626px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131850/Screenshot-2025-01-30-at-11.40.39-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131850/Screenshot-2025-01-30-at-11.40.39-PM-300x235.png 300w" alt="" width="626" height="490" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent013025&amp;t=be2bearmibe3na1">차트는 Benzinga Pro를 사용하여 생성되었습니다.</a>
애브비 주식은 단기 이동 평균선 위에서 거래되고 있으며, 8일 ($173.14) 및 20일 ($175.20) 단순 이동 평균(SMA)이 상승 신호를 보이고 있다. 그러나 장기 추세는 다른 이야기를 하고 있다. 애브비 주식은 50일 ($175.33) SMA와 밀접하게 정렬되어 있고 200일 ($178.77) SMA 아래에 있어 하방 압박이 지속되고 있음을 나타낸다. 이동 평균 수렴 발산(MACD) 지표가 -0.89로 음수를 나타내면서 이 약세 편향을 강화하고, 상대 강도 지수(RSI)가 50.39로 중립적 모멘텀을 시사한다.
전반적으로 애브비는 방향을 잡기 위해 고군분투하고 있으며, 약간의 매도 압박이 돌파 가능성을 억제하고 있다. 강력한 실적이 예상된다면 주가는 주요 저항선 수준을 넘어설 수 있지만, 현재 상황은 애브비가 추가적인 보합에 취약하다는 것을 시사한다.
<h1 class="wp-block-heading">노바티스: 상승 모멘텀을 타고 상승 중</h1>
반면, 노바티스는 확실히 상승하고 있다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent013025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-758716" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131921/Screenshot-2025-01-30-at-11.49.01-PM.png" sizes="(max-width: 626px) 100vw, 626px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131921/Screenshot-2025-01-30-at-11.49.01-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131921/Screenshot-2025-01-30-at-11.49.01-PM-300x235.png 300w" alt="" width="626" height="490" /></a></figure>
노바티스는 단기 및 중기 이동 평균선 위에서 거래되고 있으며, 8일 ($101.27), 20일 ($99.57) 및 50일 ($100.44) SMA가 모두 지지 역할을 하고 있다. MACD가 0.68로 상승 모멘텀을 나타내고, RSI가 63.61로 과매수 되지 않은 강세를 보여준다.
그러나 주가는 200일 SMA ($106.77) 아래에 있어 주의가 필요하다.
<h1 class="wp-block-heading">투자자에게 주는 시사점</h1>
실적 발표를 앞두고 노바티스는 기술적 우위를 보유하고 있으며, 더 강한 상승 구조와 상승 모멘텀을 보여준다. 반면 애브비는 범위에 갇혀 있으며 상승을 위한 촉매가 필요하다.
투자자들은 중요한 저항선 수준을 주의 깊게 지켜봐야 한다. 애브비는 $177 이상, 노바티스는 $106 이상에서 실적 발표 후 추가 움직임의 징후를 확인해야 한다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43244657/goldman-sachs-raises-abbvies-price-forecast-sees-opportunity-despite-challenges">애브비, 면역학 성장으로 모멘텀 구축, 골드만 긍정적 유지</a></li>
</ul>
사진: Romix Image via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Previews

애브비 vs 노바티스: 4분기 실적 발표 전 기술적 우위는 누구에게 있을까?

대통령 조 바이든은 백악관에서의 마지막 며칠 동안 <a href="https://www.benzinga.com/markets/cannabis/25/01/43054504/biden-commutes-sentences-of-nearly-2500-convicted-of-non-violent-drug-offenses-no-mention-of-cannabis-prisoners">비폭력 마약 범죄자 석방</a>를 우선시했지만, 틱톡? 이제는 대통령 당선자 도널드 트럼프의 문제이다.
<a href="https://apnews.com/article/tiktok-ban-trump-executive-order-1e95d9836bf6f8c0c245ed1c3234d968">AP 통신</a>에 따르면, 바이든은 금지 조치를 시행할 의사가 없으며, 이는 그의 마지막 정식 근무일인 1월 19일에 발효되고 <a href="https://www.benzinga.com/news/25/01/42995328/trump-inauguration-from-elon-musk-jeff-bezos-to-barack-obama-george-bush-and-bill-clinton-who-all-will-attend">트럼프의 취임식 하루 전</a>이다.
마감일이 다가오면서, 이 앱의 운명은 소위 &#8216;틱톡을 위한 국민 입찰&#8217;에 달려 있다. 이는 &#8220;샤크 탱크&#8221;의 케빈 오리어리(Kevin O&#8217;Leary)와 억만장자 프랭크 매코트(Frank McCourt)의 지원을 받는다. 분명히 틱톡의 미국 자산은 여전히 ​​손에 넣을 수 있지만 가격표나 거래가 <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">며칠 안에</a> 현실적으로 완료될 수 있는지 여부에 대해서는 아직 언급이 없습니다.
<h2 class="wp-block-heading">파산 블록</h2>
조앤(Joann Inc.)은 12개월 이내에 두 번째 파산 계획을 수립하고 있다. 오하이오 기반의 이 패브릭 및 공예 소매업체는 약 800개 매점의 포트폴리오 구매자를 찾고 있다.
고든 브라더스 리테일 파트너스(Gordon Brothers Retail Partners)가 "스톡킹 호스(stalking horse)" 입찰자로 나타났지만, 조앤은 여전히 더 나은 제안을 기대하고 있다. 아마도 바늘귀를 통과시키는 법을 아는 사람에게서 말이다.
이전에 82세의 소매업체는 사모펀드 레너드 그린 앤 파트너스(Leonard Green &amp; Partners)의 관리 하에 있었으며, 2011년 16억 달러의 레버리지 인수로 인수되었다. 이 회사는 부채에 묶여 있었고 (<a href="https://wolfstreet.com/2024/03/18/brick-and-mortar-meltdown-fells-another-retailer-joann-inc-files-for-bankruptcy-3-years-after-ipo/">보도에 따르면</a> 2020년 10월 31일 기준 장기 부채가 9억 2,100만 달러였음) <a href="https://www.benzinga.com/news/21/03/20048728/ipo-preview-roblox-coupang-joann-lead-busy-week-of-offerings">2021년에 상장</a>되었다.
조앤은 <a href="https://apnews.com/article/joann-bankruptcy-chapter-11-filing-75093d4032907c59a45e472dd4e23229">2024년 3월</a>에 다시 비공개로 전환되었으며, 당시 10억 달러의 총 부채를 약 5억 달러 줄이는 데 성공했다.
지난해 자구 노력이 무색해진 조앤은 최근 소매업체들의 증가하는 피해 사례에 합류하고 있다: <a href="https://www.benzinga.com/news/legal/24/12/42710619/deal-dispatch-party-city-wraps-big-lots-goes-bust-container-store-continues">몇 가지를 예로 들면</a> 파티 시티(Party City), 빅랏츠(Big Lots), LL 플로링(LL Flooring), 더바디샵(The Body Shop) 및 더 컨테이너 스토어(The Container Store) 등이 있다.
컬크랜드 앤 앨리스(Kirkland &amp; Ellis)가 법률 문제를 처리하고 있으며, 센터뷰 파트너스(Centerview Partners LLC)가 재무 자문을 제공한다. 알바레즈 앤 마살 북미(Alvarez &amp; Marsal North America, LLC)가 구조조정 과정을 감독하고 있다.
<h2 class="wp-block-heading">신규 블록</h2>
<ul>
<li>투자 회사 KKR &amp; 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>)가 골드만삭스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)를 고용하여 필리핀 핀테크 회사 마야(Maya)의 지분 매각 경매를 운영하도록 했다고 로이터가 보도했다.</li>
<li>뉴욕에 본사를 둔 KKR은 마야의 20% 이상의 지분을 보유하고 있으며, 매각이 진행된다면 마야의 가치는 20억 달러를 초과할 수 있다고 한 소식통이 전했다.</li>
<li>듀폰(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>)은 <a href="https://www.benzinga.com/news/large-cap/25/01/43028181/chemical-company-dupont-electronics-business-separation-retains-water-business">전자 사업 분리</a>를 추진하고 있다. 델라웨어 주 윌밍턴에 본사를 둔 이 회사는 거래가 11월 1일까지 완료될 것으로 예상하고 있다. 듀폰은 전략적 대안을 평가한 후 수자원 사업을 유지하기로 결정했다.</li>
<li>인제비티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>)는 성과 화학 산업 전문 분야를 매각하고 있으며, 사우스 캐롤라이나주 노스 찰스턴 부지의 일부를 매각할 계획다. 이 회사는 이익 현금 흐름을 개선하고 검토 과정을 연말까지 마무리할 것으로 기대하고 있다. 거래 여부는 <a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion">아직 미정</a>이다.</li>
<li>S&amp;W 시드 컴퍼니(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>)는 매물에 나와 있다. 이는 합병 또는 재자본화도 고려 중이며, 이는 더 큰 전략적 검토의 일환이다. 콜로라도주 롱몬트에 본사를 둔 이 회사는 호주 자회사를 이미 매각했다. 앨런 윌리츠(Alan Willits) 회장은 "우리는 주주 가치를 최적화하는 모든 이니셔티브를 지원하고 있으며, S&amp;W 시드가 향후 성공을 위해 최적의 위치에 있도록 보장하기 위해 잠재적 전략적 대안의 전체 범위를 고려할 것이다"라고 밝혔다.</li>
</ul>
참고: <a href="https://www.benzinga.com/25/01/43046722/starship-explodes-during-flight-test-elon-musk-says-success-is-uncertain-but-entertainment-is-guaranteed">스타 비행 시험 중 폭발, 일론 머스크: ‘성공은 불확실하지만 오락은 보장된다!'</a>
<h2 class="wp-block-heading">블록 업데이트</h2>
<ul>
<li>로렌코 곤칼베스(Lourenco Goncalves)는 월요일 기자 회견에서 주목을 받았다. <a href="https://www.bloomberg.com/news/articles/2025-01-14/cliffs-ceo-rips-evil-japan-and-doubles-down-on-america-first">블룸버그</a>에 따르면, 클리브랜드 클리프스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>)의 CEO는 일본을 "악당"이라고 부르며, 중국에 해로운 관행인 덤핑과 과잉 생산을 가르쳤다고 비난했다. 그의 발언은 클리브랜드 클리프스가 U.S. 스틸(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>)에 대한 새로운 입찰을 노리고 있는 가운데 나왔으며, 바이든이 일본제철(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NPSCY#OTC">NPSCY</a>)의 <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">$140억 인수 시도</a>를 차단하기로 결정한 후이다. 자신의 회사를 잠재적 구매자로 포지셔닝하면서 곤칼베스의 수사는 철강 산업의 긴장을 고조시켰다. 일본제철은 이제 트럼프에게 <a href="https://www.benzinga.com/news/25/01/42994950/nippon-steel-eyes-trump-administration-to-revive-15b-us-steel-deal-blocked-by-biden-well-do-whatever-it-takes">거래 성사를 도와달라고 요청</a>하고 있다.</li>
<li>T-모바일(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>)은 비스타 미디어(Vistar Media)를 6억 달러에 인수할 것이다. 이 통신 회사는 이 거래가 광고 사업을 강화할 것으로 기대하고 있다고 로이터가 보도했다.</li>
</ul>
지난주 생명공학 및 제약 부문 거래가 잇따랐다. 다음은 벤징가의 보도 샘플이다:
<ul>
<li>바이오젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)은 세이지 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>)의 모든 미상환 주식을 <a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say">주당 7.22달러에 인수하겠다는</a> 비공식 제안을 제출했다. 골드만삭스 애널리스트인 살빈 리히터(Salveen Richter)는 이 제안이 출산 후 우울증(PPD) 치료제인 주르주배(Zurzuvae) 런칭의 재무적 성공을 고려할 때 전략적으로 타당하다고 믿고 있다.</li>
<li>GSK plc(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)는 <a href="https://www.benzinga.com/25/01/42950025/gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion">IDRx, Inc., 위장관 간질성 종양(GIST)을 위한 정밀 치료제에 초점을 맞춘 생명공학 회사</a>를 10억 달러에 인수하기로 합의했다. 이 거래는 특정 규제 승인 이정표 후 GSK가 추가로 1억 5천만 달러를 지불해야 할 수도 있다.</li>
<li>일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 스콜피온 테라퓨틱스(Scorpion Therapeutics)의 초기 단계 <a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion">암 치료 프로그램을 25억 달러에 인수</a>했다.</li>
<li>브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)와 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)와 마찬가지로, 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)는 <a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal">150억 달러 거래로</a> 신경정신적 포트폴리오를 강화하려고 합니다.</li>
<li>크라운 래버러토리즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>)는 레반스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>)의 모든 미상환 보통주를 주당 3.10달러에 인수하겠다고 제안했다.</li>
<li>셀러리어스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>)는 디코이 테라퓨틱스(Decoy Therapeutics)와의 거래를 체결했다. 이 회사는 펩타이드 접합 치료제에 초점을 맞춘 초기 단계 생명공학 회사이다. 통합된 개체는 호흡기 질환과 위장관 종양학의 미충족 요구 사항을 목표로 할 것이다.</li>
<li>란테우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>)는 <a href="https://www.benzinga.com/m-a/25/01/42937565/lantheus-strengthens-radiopharmaceutical-leadership-with-350m-acquisition-of-life-molecular-imaging">3억 5천만 달러에 라이프 몰레큘러 이미징을 인수하여</a> 방사선 치료제 분야에서의 입지를 강화했다.</li>
<li> </li>
</ul>
지난주 딜 디스패치의 에디션은 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-td-%EC%9D%80%ED%96%89%EC%9D%B4-%EC%B0%B0%EC%8A%A4-%EC%8A%88%EC%99%91-%EC%A7%80%EB%B6%84%EC%9D%84-%ED%8C%90%EB%A7%A4%ED%95%A0%EA%B9%8C-%EC%95%84/" target="_blank" rel="noopener">여기를 클릭하세요</a><a href="https://www.benzinga.com/ma/25/01/42921113/deal-dispatch-td-bank-charles-schwab-eyenovia-smart-share-hit-auction-block">.</a>
지금 읽기:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/43055513/eccentric-billionaire-howard-hughes-former-miami-estate-on-market-for-55-5-million">엑센트릭한 억만장자, 전설적인 영화 제작자 하워드 휴즈의 전 마이애미 저택이 5천 550만 달러에 매물로 나왔습니다.</a></li>
</ul>
이미지는 Shutterstock의 사진을 사용하여 생성되었습니다.


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

BIIB

LNTH

NGVT

NPSCY

RVNC

SAGE

SANW

SLRX

TMUS

딜 디스패치: 바이든이 틱톡 금지를 트럼프에게 넘기고, 또 다른 유명 소매업체 파산

시장이 불안정하고 혼란스러운 시기에는 많은 투자자들이 배당 수익률이 높은 주식으로 눈을 돌린다. 이러한 주식은 높은 잉여 현금 흐름을 가지고 있으며 주주들에게 높은 배당금을 지급하여 보상을 한다.
벤징가 독자들은 <a href="https://www.benzinga.com/analyst-stock-ratings">애널리스트 주식 등급</a> 페이지를 방문하여 자신이 선호하는 주식에 대한 최신 애널리스트 의견을 검토할 수 있다. 트레이더들은 벤징가의 방대한 애널리스트 등급 데이터베이스를 필터링하여 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">애널리스트 정확도</a>에 따라 정렬할 수 있다.
아래는 의료 부문에서 배당 수익률이 높은 세 개의 주식에 대한 가장 정확한 애널리스트들의 평가이다.
<h3 class="wp-block-heading">암젠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</h3>
<ul>
<li>배당 수익률: 3.67%</li>
<li>파이퍼 샌들러의애널리스트 데이비드 암셀렘(David Amsellem)은 1월 2일 주식에 대해 비중 확대 등급을 유지하고 목표 주가를 $344에서 $310으로 하향 조정했다. 이 애널리스트의 정확도는 66%이다.</li>
<li>BofA 증권의애널리스트 팀 앤더슨(Tim Anderson)은 12월 10일 주식에 대해 언더퍼폼 등급을 재부여하고 목표 주가를 $256로 설정했다. 이 애널리스트의 정확도는 63%이다.</li>
<li>최근 뉴스: 암젠은 12월 10일 1분기 배당금을 주당 $2.25에서 $2.38로 6% 인상했다.</li>
<li>Benzinga Pro의 실시간 뉴스 피드에서 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">최신 AMGN 뉴스를</a> 알림 받았다.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-716759" style="width: 619px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12.png" sizes="(max-width: 902px) 100vw, 902px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12-768x705.png 768w" alt="" width="902" height="828" /></a></figure>
<h3 class="wp-block-heading">애브비 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul>
<li>배당 수익률: 3.66%</li>
<li>BofA 증권의애널리스트 팀 앤더슨(Tim Anderson)은 12월 10일 주식에 대해 중립 등급을 재부여하고 목표 주가를 $191로 설정했다. 이 애널리스트의 정확도는 63%이다.</li>
<li>리링크 파트너스의 애널리스트 데이비드 라이징거(David Risinger)는 11월 22일 주식을 시장 평균에서 아웃퍼폼으로 상향 조정하고 목표 주가를 $206으로 설정했다. 이 애널리스트의 정확도는 75%이다.</li>
<li>최근 뉴스: 애브비는 12월 13일 님블 테라퓨틱스(Nimble Therapeutics)를 인수할 계획을 발표했다.</li>
<li>Benzinga Pro의 실시간 뉴스 피드에서 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">최신 ABBV 뉴스를</a> 알림 받았다.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-716760" style="width: 670px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13.png" sizes="(max-width: 917px) 100vw, 917px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13-768x709.png 768w" alt="" width="917" height="847" /></a></figure>
<h3 class="wp-block-heading">CVS 헬스 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>배당 수익률: 6.02%</li>
<li>도이치 뱅크의 애널리스트 조지 힐(George Hill)은 12월 3일 주식을 보유에서 매수로 상향 조정하고 목표 주가를 $66으로 설정했다. 이 애널리스트의 정확도는 60%이다.</li>
<li>트루이스트 증권의 애널리스트 데이비드 맥도날드(David Macdonald)는 11월 20일 주식에 대해 매수 등급을 재확인하고 목표 주가를 $76에서 $67로 하향 조정했다. 이 애널리스트의 정확도는 63%이다.</li>
<li>최근 뉴스: 최근 법무부(DOJ)는 CVS가 2013년부터 불법 처방전으로 오피오이드 조합약과 과다량을 조제하여 관리 약물 법을 위반했다고 주장했다.</li>
<li>Benzinga Pro의 차트 도구가 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">CVS 주식의 추세</a>를 식별하는 데 도움을 주었다.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-716761" style="width: 584px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14.png" sizes="(max-width: 912px) 100vw, 912px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14-768x712.png 768w" alt="" width="912" height="845" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio">
<div class="wp-block-embed__wrapper"><iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&amp;feature=oembed" width="500" height="281" frameborder="0" allowfullscreen="allowfullscreen"></iframe></div>
</figure>
더 읽기:
<ul>
<li><a href="https://www.benzinga.com/25/01/42763645/how-to-earn-500-a-month-from-acuity-brands-stock-ahead-of-q1-earnings">애큐티 브랜드 주식으로 월 $500를 버는 방법</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Price Target

Pre-Market Outlook

월가에서 가장 정확한 분석가들이 주목: 고배당 수익을 창출하는 3개의 헬스케어 주식

슈왑 미국 배당주 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>)는 12월에 7% 이상 하락하면서 지난 한 달 동안 1년간 상승폭의 절반 이상을 반납했다. <a href="https://www.benzinga.com/24/12/42528079/this-high-yield-dividend-etf-is-undergoing-a-harsh-reversal-signaling-bearish-trends-here-what-you-need-to-know" target="_blank" rel="noopener">SCHD 펀드가 하락한 이유를 살펴보자.</a>
알아야 할 내용: 슈왑 미국 배당주 ETF는 4개의 제약주가 펀드 전체 보유 자산의 15.83%를 차지해 헬스케어 부문에 큰 비중을 두고 있다. 헬스케어 섹터는 최근 도널드 트럼프 대통령 당선인의 행정부 책임자 임명 및 <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction" target="_blank" rel="noopener">정책 변화</a>에 대한 불확실성이 높아지면서 실적이 저조했다.
<h2>헬스케어 부문 보유 종목</h2>
브리스톨 마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)는 펀드 내에서 가장 큰 제약 보유 종목으로, 자산의 4.64%를 차지한다. 지난 한달 동안 주가는 2.6% 하락했다.
화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)도 펀드의 상위 10개 보유 종목에 속흔다. 백신 제조사 화이자는 앞으로 불확실한 정치 및 규제 환경에 직면하면서 대선 이후 5% 이상 하락했다.
애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)와 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)도 헬스케어 보유 종목이다. 애브비 주가는 소폭 하락했지만 암젠 주가는 12월에 체중 감량 약물 후보인 마리타이드(MariTide)의 실망스러운 <a href="https://www.benzinga.com/content/42377651/amgen-stock-falls-on-weight-loss-drug-data-overreaction-or-fair" target="_blank" rel="noopener">임상시험 </a>결과로 인해 10% 이상 하락했다.
금리: 슈왑 미국 배당주 ETF에 영향을 미칠 수 있는 또 다른 요인은 불확실한 금리 환경이다. 저금리 환경에서는 배당금이 투자자에게 더 매력적으로 다가오는 경향이 있다. 최근 연준의 발언에 따르면 인플레이션이 연준의 목표 금리인 2%를 상회하는 등 매파적인 전망이 나온다.
또한 트럼프가 해외 수입품에 대한 관세를 인상하겠다고 공약한 만큼 차기 트럼프 행정부가 인플레이션을 재점화하고 금리를 더 오래 유지할 수 있는 요인으로 작용할 수 있다.
금리가 높으면 채권 및 기타 채권형 증권의 수익률 경쟁이 치열해져 배당 수익률은 상대적으로 매력도가 떨어지게 된다.
이미지: Shutterstock
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%94%EB%B9%84%EB%94%94%EC%95%84-%EC%A3%BC%EA%B0%80-4-%EA%B0%80%EA%B9%8C%EC%9D%B4-%EC%83%81%EC%8A%B9%ED%95%9C-%EC%9D%B4%EC%9C%A0%EB%8A%94/" target="_blank" rel="noopener">엔비디아, 주가 4% 가까이 상승한 이유는?</a>
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Specialty ETFs

ETFs

SCHD

슈왑 미국 배당주 ETF(SCHD), 12월에 7% 이상 하락한 이유는?

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다.
강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다.
2024년 바이오제약 주식은 9.6% 상승하여 S&amp;P 500의 28.5% 상승률에 미치지 못했다. 그러나 JP모건 애널리스트들은 몇몇 주요 기업에 대해 긍정적인 전망을 유지하고 있다.
JP모건에서 가장 많이 추천하는 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 당뇨병 및 비만 치료제인 <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">마운자로(Mounjaro)와 젭바운드(Zepbound)</a>에서 지속적인 성장을 보일 것으로 예상된다. 또한 JP모건은 일라이 릴리의 강력한 파이프라인을 강조하면서 2030년대까지 두 자릿수 매출과 수익 성장을 예측했다.
브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)는 최고 매출 100억 달러를 달성할 수 있는 조현병 치료제인 코벤피(Cobenfy)의 강력한 잠재력으로 JP모건의 &#8216;포커스 리스트&#8217;에 추가되었다.
마찬가지로 머크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)와 리제네론 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an">주요 제품에 영향을 미치는</a> <a href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare">경쟁 압력</a> 및 지역 역학과 관련된 2024년의 어려움에 이어 2025년에는 회복될 것이르오 예상된다.
길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)는 <a href="https://www.benzinga.com/quote/GILD">HIV 예방을 위한</a> 레나카파비르(lenacapavir)의 2025년 중반 출시가 예상됨에 따라 성장할 것으로 예상된다.
또한 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)는 단기적인 <a href="https://www.benzinga.com/quote/ABBV">파이프라인 개발</a>이 적음에도 불구하고 스카이리지(Skyrizi)와 린보크(Rinvoq) 판매 호조에 힘입어 밸류에이션이 매력적이라고 보았다.
한편, 동물 건강 관련 주식도 2025년에 반등할 것으로 예상한다. JP 모건은 조에티스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>)를 이 분야에서 가장 강력한 선택지로 보고 있으며, 고배당 매출 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" target="_blank" rel="noreferrer noopener">성장과 마진 확장</a>의 잠재력을 언급했다. 아이덱스 래버러토리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>)는 또 다른 다른 확실한 선택이며, 성과는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" target="_blank" rel="noreferrer noopener">수의사 방문 수 회복</a>에 달려 있다. 한편 엘랑코 애니멀 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" target="_blank" rel="noreferrer noopener">신제품 출시</a>와 관련된 불확실성에 직면해 있다.
그리고 특수 의약품 부문은 2024년에 가격 안정성과 공급 역학 개선의 혜택을 받아 조기에 안정화 조짐을 보였다. 페리고(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>)와 비아트리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)는 유망한 기회로 강조되었으며 테바 파마슈티컬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)는 올해 강력한 임상 시험 <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" target="_blank" rel="noreferrer noopener">결과를 발표했지만</a> 성장 문제에 직면할 수 있다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%ED%80%80%ED%85%80-%EC%BB%B4%ED%93%A8%ED%8C%85-%EB%B8%94%EB%9E%99%EB%B2%A0%EB%A6%AC-%EB%A3%A8%EC%8B%9C%EB%93%9C-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EB%8C%80-%EC%83%81%EC%8A%B9%ED%95%9C/">퀀텀 컴퓨팅, 블랙베리, 루시드 등 지난주 최대 상승한 중형주 (12월 16일~20일)</a>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ELAN

IDXX

PRGO

VTRS

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 모놀리식 파워 시스템즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>)의 주식은 24.68% 하락했다. 이는 엣지워터 리서치(Edgewater Research)의 분석 보고서에 따라 모놀리식의 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 블랙웰(Blackwell) GPU에 대한 할당이 전력 관리 IC의 성능 문제로 위험에 처해 있다고 밝힌 후 발생한 일이다.
2. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 24.23% 하락했다. 이는 회사가 최근  <a href="https://www.benzinga.com//node/41938588" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2024년 9월 30일 종료 분기 보고서를 제때</a> 제출할 수 없다고 발표한 후 주가가 급락했다.
3. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주식은 21.31% 하락했다. 이는 도널드 트럼프 대통령 당선인이 로버트 F. 케네디 주니어를 보건복지부(HHS) 장관으로 지명한 후 <a href="https://www.benzinga.com//node/42013119" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">백신 주식에 대한 압박</a>이 발생했기 때문이다.
4. 레이도스 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>)의 주식은 19.04% 하락했다. 이는 트럼프 대통령 당선인이 인수 기간 동안 연방 정부 주요직 임명을 했기 때문으로, 투자자들은 &#8220;<a href="https://www.benzinga.com//node/42013424" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">정부 효율성 부서</a>&#8220;에서의 가능한 삭감의 영향을 평가할 수 있다.
5. 먼데이닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>)의 주식은 회사가 3분기 실적이 예상치를 웃돌고 연간 전망을 상향 조정했음에도 <a href="https://www.benzinga.com//node/41877454" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">불구하고</a> 지난주 18.94% 하락했다.
6. 백스사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>)의 주식은 18.60% 하락했다. 이는 도널드 트럼프 대통령 당선인이 로버트 F. 케네디 주니어를 HHS 장관으로 지명한 후 백신 주식에 대한 압박이 발생했기 때문이다.
7. 부즈 앨런 해밀턴 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>)의 주식은 18.59% 하락했다.
8. 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)의 주식은 17.30% 하락했다. 이는 2상 EMPOWER 시험이 <a href="https://www.benzinga.com/general/biotech/24/11/41881546/abbvie-9billion-schizophrenia-studies-bristol-myers-stock-surges" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주요 목표</a>를 달성하지 못했다고 발표한 후 발생한 일이다.
9. CACI 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>)의 주식은 17.16% 하락했다.
10. 샤오펑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>)의 주식은 16.89% 하락했다. 이는 미국에 상장된 중국 주식의 광범위한 하락세를 반영한 것이다. 이러한 시장 변화는 트럼프 당선인의 행정부 인사를 둘러싼 우려의 영향을 받을 수 있으며, 이는 <a href="https://www.benzinga.com//node/41946780" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">중국에 대한 더욱 강경한 입장</a>을 나타낼 수 있다.
또한 읽어보세요:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%87%BC%ED%94%BC%ED%8C%8C%EC%9D%B4-%EB%94%94%EC%A6%88%EB%8B%88-%EB%B0%8F-%EC%BD%94%EC%9D%B8%EB%B2%A0%EC%9D%B4%EC%8A%A4%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC/" target="_blank" rel="noopener">쇼피파이, 디즈니 및 코인베이스는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 11일-15일)</a></li>
</ul>
이미지 출처: Robert Way via Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

AbbVie

뉴스

에 대한 최신 뉴스 AbbVie (NYSE:ABBV) 주식

토요일, 5월 17, 2025

금요일, 5월 16, 2025

수요일, 4월 30, 2025

금요일, 4월 25, 2025

금요일, 4월 11, 2025

목요일, 1월 30, 2025

일요일, 1월 19, 2025

토요일, 1월 04, 2025

화요일, 12월 24, 2024

월요일, 12월 23, 2024

일요일, 11월 17, 2024

금요일, 11월 15, 2024

일요일, 7월 21, 2024

일요일, 7월 07, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌